id	sid	tid	token	lemma	pos
cord-352096-cc3dzycl	1	1	key	key	NN
cord-352096-cc3dzycl	1	2	:	:	:
cord-352096-cc3dzycl	2	1	cord-352096-cc3dzycl	cord-352096-cc3dzycl	NFP
cord-352096-cc3dzycl	2	2	authors	author	NNS
cord-352096-cc3dzycl	2	3	:	:	:
cord-352096-cc3dzycl	2	4	Richman	Richman	NNP
cord-352096-cc3dzycl	2	5	,	,	,
cord-352096-cc3dzycl	2	6	Douglas	Douglas	NNP
cord-352096-cc3dzycl	2	7	D.	D.	NNP
cord-352096-cc3dzycl	2	8	title	title	NN
cord-352096-cc3dzycl	2	9	:	:	:
cord-352096-cc3dzycl	2	10	Antiviral	Antiviral	NNP
cord-352096-cc3dzycl	2	11	Drug	Drug	NNP
cord-352096-cc3dzycl	2	12	Discovery	Discovery	NNP
cord-352096-cc3dzycl	3	1	To	to	TO
cord-352096-cc3dzycl	3	2	Address	address	VB
cord-352096-cc3dzycl	3	3	the	the	DT
cord-352096-cc3dzycl	3	4	COVID-19	COVID-19	NNP
cord-352096-cc3dzycl	3	5	Pandemic	Pandemic	NNP
cord-352096-cc3dzycl	3	6	date	date	NN
cord-352096-cc3dzycl	3	7	:	:	:
cord-352096-cc3dzycl	3	8	2020	2020	CD
cord-352096-cc3dzycl	3	9	-	-	HYPH
cord-352096-cc3dzycl	3	10	09	09	CD
cord-352096-cc3dzycl	3	11	-	-	SYM
cord-352096-cc3dzycl	3	12	25	25	CD
cord-352096-cc3dzycl	3	13	journal	journal	NN
cord-352096-cc3dzycl	3	14	:	:	:
cord-352096-cc3dzycl	4	1	mBio	mbio	NN
cord-352096-cc3dzycl	4	2	DOI	doi	NN
cord-352096-cc3dzycl	4	3	:	:	:
cord-352096-cc3dzycl	4	4	10.1128	10.1128	CD
cord-352096-cc3dzycl	4	5	/	/	SYM
cord-352096-cc3dzycl	4	6	mbio.02134	mbio.02134	NNP
cord-352096-cc3dzycl	4	7	-	-	HYPH
cord-352096-cc3dzycl	4	8	20	20	CD
cord-352096-cc3dzycl	4	9	sha	sha	NN
cord-352096-cc3dzycl	4	10	:	:	:
cord-352096-cc3dzycl	4	11	2c59dbd6f8e854bbc912cbe2a771faedc85c226f	2c59dbd6f8e854bbc912cbe2a771faedc85c226f	CD
cord-352096-cc3dzycl	4	12	doc_id	doc_id	CD
cord-352096-cc3dzycl	4	13	:	:	:
cord-352096-cc3dzycl	4	14	352096	352096	CD
cord-352096-cc3dzycl	4	15	cord_uid	cord_uid	NNS
cord-352096-cc3dzycl	4	16	:	:	:
cord-352096-cc3dzycl	4	17	cc3dzycl	cc3dzycl	.
cord-352096-cc3dzycl	5	1	The	the	DT
cord-352096-cc3dzycl	5	2	magnitude	magnitude	NN
cord-352096-cc3dzycl	5	3	of	of	IN
cord-352096-cc3dzycl	5	4	the	the	DT
cord-352096-cc3dzycl	5	5	morbidity	morbidity	NN
cord-352096-cc3dzycl	5	6	and	and	CC
cord-352096-cc3dzycl	5	7	mortality	mortality	NN
cord-352096-cc3dzycl	5	8	inflicted	inflict	VBN
cord-352096-cc3dzycl	5	9	upon	upon	IN
cord-352096-cc3dzycl	5	10	the	the	DT
cord-352096-cc3dzycl	5	11	global	global	JJ
cord-352096-cc3dzycl	5	12	population	population	NN
cord-352096-cc3dzycl	5	13	in	in	IN
cord-352096-cc3dzycl	5	14	less	less	JJR
cord-352096-cc3dzycl	5	15	than	than	IN
cord-352096-cc3dzycl	5	16	1	1	CD
cord-352096-cc3dzycl	5	17	year	year	NN
cord-352096-cc3dzycl	5	18	has	have	VBZ
cord-352096-cc3dzycl	5	19	driven	drive	VBN
cord-352096-cc3dzycl	5	20	the	the	DT
cord-352096-cc3dzycl	5	21	inescapable	inescapable	JJ
cord-352096-cc3dzycl	5	22	conclusion	conclusion	NN
cord-352096-cc3dzycl	5	23	that	that	IN
cord-352096-cc3dzycl	5	24	the	the	DT
cord-352096-cc3dzycl	5	25	discovery	discovery	NN
cord-352096-cc3dzycl	5	26	and	and	CC
cord-352096-cc3dzycl	5	27	development	development	NN
cord-352096-cc3dzycl	5	28	of	of	IN
cord-352096-cc3dzycl	5	29	effective	effective	JJ
cord-352096-cc3dzycl	5	30	antiviral	antiviral	JJ
cord-352096-cc3dzycl	5	31	drugs	drug	NNS
cord-352096-cc3dzycl	5	32	for	for	IN
cord-352096-cc3dzycl	5	33	COVID-19	COVID-19	NNP
cord-352096-cc3dzycl	5	34	are	be	VBP
cord-352096-cc3dzycl	5	35	urgent	urgent	JJ
cord-352096-cc3dzycl	5	36	and	and	CC
cord-352096-cc3dzycl	5	37	should	should	MD
cord-352096-cc3dzycl	5	38	be	be	VB
cord-352096-cc3dzycl	5	39	prioritized	prioritize	VBN
cord-352096-cc3dzycl	5	40	.	.	.
cord-352096-cc3dzycl	6	1	The	the	DT
cord-352096-cc3dzycl	6	2	antiviral	antiviral	JJ
cord-352096-cc3dzycl	6	3	drug	drug	NN
cord-352096-cc3dzycl	6	4	discovery	discovery	NN
cord-352096-cc3dzycl	6	5	programs	program	NNS
cord-352096-cc3dzycl	6	6	that	that	WDT
cord-352096-cc3dzycl	6	7	emerged	emerge	VBD
cord-352096-cc3dzycl	6	8	for	for	IN
cord-352096-cc3dzycl	6	9	HIV	HIV	NNP
cord-352096-cc3dzycl	6	10	and	and	CC
cord-352096-cc3dzycl	6	11	hepatitis	hepatitis	NNP
cord-352096-cc3dzycl	6	12	C	C	NNP
cord-352096-cc3dzycl	6	13	virus	virus	NN
cord-352096-cc3dzycl	6	14	have	have	VBP
cord-352096-cc3dzycl	6	15	enabled	enable	VBN
cord-352096-cc3dzycl	6	16	technology	technology	NN
cord-352096-cc3dzycl	6	17	and	and	CC
cord-352096-cc3dzycl	6	18	expertise	expertise	NN
cord-352096-cc3dzycl	6	19	to	to	TO
cord-352096-cc3dzycl	6	20	accelerate	accelerate	VB
cord-352096-cc3dzycl	6	21	this	this	DT
cord-352096-cc3dzycl	6	22	process	process	NN
cord-352096-cc3dzycl	6	23	for	for	IN
cord-352096-cc3dzycl	6	24	SARS	SARS	NNP
cord-352096-cc3dzycl	6	25	-	-	HYPH
cord-352096-cc3dzycl	6	26	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	6	27	.	.	.
cord-352096-cc3dzycl	7	1	The	the	DT
cord-352096-cc3dzycl	7	2	description	description	NN
cord-352096-cc3dzycl	7	3	of	of	IN
cord-352096-cc3dzycl	7	4	candidate	candidate	NN
cord-352096-cc3dzycl	7	5	lead	lead	VB
cord-352096-cc3dzycl	7	6	inhibitors	inhibitor	NNS
cord-352096-cc3dzycl	7	7	for	for	IN
cord-352096-cc3dzycl	7	8	the	the	DT
cord-352096-cc3dzycl	7	9	viral	viral	JJ
cord-352096-cc3dzycl	7	10	main	main	JJ
cord-352096-cc3dzycl	7	11	protease	protease	NN
cord-352096-cc3dzycl	7	12	(	(	-LRB-
cord-352096-cc3dzycl	7	13	M(pro	M(pro	NNP
cord-352096-cc3dzycl	7	14	)	)	-RRB-
cord-352096-cc3dzycl	7	15	)	)	-RRB-
cord-352096-cc3dzycl	7	16	exemplifies	exemplify	VBZ
cord-352096-cc3dzycl	7	17	this	this	DT
cord-352096-cc3dzycl	7	18	accelerated	accelerated	JJ
cord-352096-cc3dzycl	7	19	approach	approach	NN
cord-352096-cc3dzycl	7	20	and	and	CC
cord-352096-cc3dzycl	7	21	reminds	remind	VBZ
cord-352096-cc3dzycl	7	22	us	-PRON-	PRP
cord-352096-cc3dzycl	7	23	of	of	IN
cord-352096-cc3dzycl	7	24	the	the	DT
cord-352096-cc3dzycl	7	25	needs	need	NNS
cord-352096-cc3dzycl	7	26	and	and	CC
cord-352096-cc3dzycl	7	27	opportunities	opportunity	NNS
cord-352096-cc3dzycl	7	28	for	for	IN
cord-352096-cc3dzycl	7	29	addressing	address	VBG
cord-352096-cc3dzycl	7	30	this	this	DT
cord-352096-cc3dzycl	7	31	pandemic	pandemic	NN
cord-352096-cc3dzycl	7	32	.	.	.
cord-352096-cc3dzycl	8	1	T	T	NNP
cord-352096-cc3dzycl	8	2	he	-PRON-	PRP
cord-352096-cc3dzycl	8	3	need	need	VBP
cord-352096-cc3dzycl	8	4	for	for	IN
cord-352096-cc3dzycl	8	5	more	more	RBR
cord-352096-cc3dzycl	8	6	effective	effective	JJ
cord-352096-cc3dzycl	8	7	antiviral	antiviral	JJ
cord-352096-cc3dzycl	8	8	drugs	drug	NNS
cord-352096-cc3dzycl	8	9	against	against	IN
cord-352096-cc3dzycl	8	10	SARS	SARS	NNP
cord-352096-cc3dzycl	8	11	-	-	HYPH
cord-352096-cc3dzycl	8	12	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	8	13	is	be	VBZ
cord-352096-cc3dzycl	8	14	undeniable	undeniable	JJ
cord-352096-cc3dzycl	8	15	.	.	.
cord-352096-cc3dzycl	9	1	Even	even	RB
cord-352096-cc3dzycl	9	2	with	with	IN
cord-352096-cc3dzycl	9	3	the	the	DT
cord-352096-cc3dzycl	9	4	identification	identification	NN
cord-352096-cc3dzycl	9	5	of	of	IN
cord-352096-cc3dzycl	9	6	the	the	DT
cord-352096-cc3dzycl	9	7	first	first	JJ
cord-352096-cc3dzycl	9	8	effective	effective	JJ
cord-352096-cc3dzycl	9	9	drug	drug	NN
cord-352096-cc3dzycl	9	10	for	for	IN
cord-352096-cc3dzycl	9	11	coronavirus	coronavirus	NN
cord-352096-cc3dzycl	9	12	infection	infection	NN
cord-352096-cc3dzycl	9	13	,	,	,
cord-352096-cc3dzycl	9	14	remdesivir	remdesivir	NNP
cord-352096-cc3dzycl	9	15	,	,	,
cord-352096-cc3dzycl	9	16	the	the	DT
cord-352096-cc3dzycl	9	17	need	need	NN
cord-352096-cc3dzycl	9	18	for	for	IN
cord-352096-cc3dzycl	9	19	additional	additional	JJ
cord-352096-cc3dzycl	9	20	drugs	drug	NNS
cord-352096-cc3dzycl	9	21	remains	remain	VBZ
cord-352096-cc3dzycl	9	22	critical	critical	JJ
cord-352096-cc3dzycl	9	23	.	.	.
cord-352096-cc3dzycl	10	1	Regardless	regardless	RB
cord-352096-cc3dzycl	10	2	of	of	IN
cord-352096-cc3dzycl	10	3	whether	whether	IN
cord-352096-cc3dzycl	10	4	or	or	CC
cord-352096-cc3dzycl	10	5	when	when	WRB
cord-352096-cc3dzycl	10	6	a	a	DT
cord-352096-cc3dzycl	10	7	vaccine	vaccine	NN
cord-352096-cc3dzycl	10	8	becomes	become	VBZ
cord-352096-cc3dzycl	10	9	available	available	JJ
cord-352096-cc3dzycl	10	10	,	,	,
cord-352096-cc3dzycl	10	11	antivirals	antiviral	NNS
cord-352096-cc3dzycl	10	12	for	for	IN
cord-352096-cc3dzycl	10	13	SARS	SARS	NNP
cord-352096-cc3dzycl	10	14	-	-	HYPH
cord-352096-cc3dzycl	10	15	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	10	16	will	will	MD
cord-352096-cc3dzycl	10	17	still	still	RB
cord-352096-cc3dzycl	10	18	be	be	VB
cord-352096-cc3dzycl	10	19	needed	need	VBN
cord-352096-cc3dzycl	10	20	for	for	IN
cord-352096-cc3dzycl	10	21	several	several	JJ
cord-352096-cc3dzycl	10	22	reasons	reason	NNS
cord-352096-cc3dzycl	10	23	:	:	:
cord-352096-cc3dzycl	10	24	the	the	DT
cord-352096-cc3dzycl	10	25	unlikelihood	unlikelihood	NN
cord-352096-cc3dzycl	10	26	that	that	IN
cord-352096-cc3dzycl	10	27	a	a	DT
cord-352096-cc3dzycl	10	28	vaccine	vaccine	NN
cord-352096-cc3dzycl	10	29	will	will	MD
cord-352096-cc3dzycl	10	30	be	be	VB
cord-352096-cc3dzycl	10	31	100	100	CD
cord-352096-cc3dzycl	10	32	%	%	NN
cord-352096-cc3dzycl	10	33	effective	effective	JJ
cord-352096-cc3dzycl	10	34	,	,	,
cord-352096-cc3dzycl	10	35	the	the	DT
cord-352096-cc3dzycl	10	36	incompleteness	incompleteness	NN
cord-352096-cc3dzycl	10	37	of	of	IN
cord-352096-cc3dzycl	10	38	vaccine	vaccine	NN
cord-352096-cc3dzycl	10	39	coverage	coverage	NN
cord-352096-cc3dzycl	10	40	because	because	IN
cord-352096-cc3dzycl	10	41	of	of	IN
cord-352096-cc3dzycl	10	42	both	both	DT
cord-352096-cc3dzycl	10	43	vaccine	vaccine	NN
cord-352096-cc3dzycl	10	44	hesitancy	hesitancy	NN
cord-352096-cc3dzycl	10	45	and	and	CC
cord-352096-cc3dzycl	10	46	the	the	DT
cord-352096-cc3dzycl	10	47	numerous	numerous	JJ
cord-352096-cc3dzycl	10	48	logistical	logistical	JJ
cord-352096-cc3dzycl	10	49	challenges	challenge	NNS
cord-352096-cc3dzycl	10	50	to	to	IN
cord-352096-cc3dzycl	10	51	accomplishing	accomplish	VBG
cord-352096-cc3dzycl	10	52	prompt	prompt	JJ
cord-352096-cc3dzycl	10	53	large	large	JJ
cord-352096-cc3dzycl	10	54	-	-	HYPH
cord-352096-cc3dzycl	10	55	scale	scale	NN
cord-352096-cc3dzycl	10	56	immunization	immunization	NN
cord-352096-cc3dzycl	10	57	of	of	IN
cord-352096-cc3dzycl	10	58	the	the	DT
cord-352096-cc3dzycl	10	59	majority	majority	NN
cord-352096-cc3dzycl	10	60	of	of	IN
cord-352096-cc3dzycl	10	61	the	the	DT
cord-352096-cc3dzycl	10	62	population	population	NN
cord-352096-cc3dzycl	10	63	,	,	,
cord-352096-cc3dzycl	10	64	the	the	DT
cord-352096-cc3dzycl	10	65	possibility	possibility	NN
cord-352096-cc3dzycl	10	66	of	of	IN
cord-352096-cc3dzycl	10	67	limited	limited	JJ
cord-352096-cc3dzycl	10	68	durability	durability	NN
cord-352096-cc3dzycl	10	69	of	of	IN
cord-352096-cc3dzycl	10	70	vaccine	vaccine	NN
cord-352096-cc3dzycl	10	71	protection	protection	NN
cord-352096-cc3dzycl	10	72	,	,	,
cord-352096-cc3dzycl	10	73	the	the	DT
cord-352096-cc3dzycl	10	74	need	need	NN
cord-352096-cc3dzycl	10	75	for	for	IN
cord-352096-cc3dzycl	10	76	additional	additional	JJ
cord-352096-cc3dzycl	10	77	prophylaxis	prophylaxis	NN
cord-352096-cc3dzycl	10	78	for	for	IN
cord-352096-cc3dzycl	10	79	high	high	JJ
cord-352096-cc3dzycl	10	80	-	-	HYPH
cord-352096-cc3dzycl	10	81	risk	risk	NN
cord-352096-cc3dzycl	10	82	subjects	subject	NNS
cord-352096-cc3dzycl	10	83	and	and	CC
cord-352096-cc3dzycl	10	84	poor	poor	JJ
cord-352096-cc3dzycl	10	85	vaccine	vaccine	NN
cord-352096-cc3dzycl	10	86	responders	responder	NNS
cord-352096-cc3dzycl	10	87	,	,	,
cord-352096-cc3dzycl	10	88	and	and	CC
cord-352096-cc3dzycl	10	89	the	the	DT
cord-352096-cc3dzycl	10	90	future	future	JJ
cord-352096-cc3dzycl	10	91	value	value	NN
cord-352096-cc3dzycl	10	92	of	of	IN
cord-352096-cc3dzycl	10	93	effective	effective	JJ
cord-352096-cc3dzycl	10	94	antiviral	antiviral	JJ
cord-352096-cc3dzycl	10	95	treatment	treatment	NN
cord-352096-cc3dzycl	10	96	for	for	IN
cord-352096-cc3dzycl	10	97	Middle	Middle	NNP
cord-352096-cc3dzycl	10	98	East	East	NNP
cord-352096-cc3dzycl	10	99	respiratory	respiratory	JJ
cord-352096-cc3dzycl	10	100	syndrome	syndrome	NN
cord-352096-cc3dzycl	10	101	(	(	-LRB-
cord-352096-cc3dzycl	10	102	MERS	MERS	NNP
cord-352096-cc3dzycl	10	103	)	)	-RRB-
cord-352096-cc3dzycl	10	104	and	and	CC
cord-352096-cc3dzycl	10	105	new	new	JJ
cord-352096-cc3dzycl	10	106	coronaviruses	coronaviruse	NNS
cord-352096-cc3dzycl	10	107	that	that	WDT
cord-352096-cc3dzycl	10	108	will	will	MD
cord-352096-cc3dzycl	10	109	likely	likely	RB
cord-352096-cc3dzycl	10	110	emerge	emerge	VB
cord-352096-cc3dzycl	10	111	from	from	IN
cord-352096-cc3dzycl	10	112	zoonoses	zoonosis	NNS
cord-352096-cc3dzycl	10	113	.	.	.
cord-352096-cc3dzycl	11	1	Unmet	unmet	JJ
cord-352096-cc3dzycl	11	2	needs	need	NNS
cord-352096-cc3dzycl	11	3	for	for	IN
cord-352096-cc3dzycl	11	4	new	new	JJ
cord-352096-cc3dzycl	11	5	antivirals	antiviral	NNS
cord-352096-cc3dzycl	11	6	include	include	VBP
cord-352096-cc3dzycl	11	7	additional	additional	JJ
cord-352096-cc3dzycl	11	8	and	and	CC
cord-352096-cc3dzycl	11	9	greater	great	JJR
cord-352096-cc3dzycl	11	10	efficacy	efficacy	NN
cord-352096-cc3dzycl	11	11	,	,	,
cord-352096-cc3dzycl	11	12	oral	oral	JJ
cord-352096-cc3dzycl	11	13	bioavailability	bioavailability	NN
cord-352096-cc3dzycl	11	14	,	,	,
cord-352096-cc3dzycl	11	15	utility	utility	NN
cord-352096-cc3dzycl	11	16	for	for	IN
cord-352096-cc3dzycl	11	17	prophylaxis	prophylaxis	NN
cord-352096-cc3dzycl	11	18	as	as	RB
cord-352096-cc3dzycl	11	19	well	well	RB
cord-352096-cc3dzycl	11	20	as	as	IN
cord-352096-cc3dzycl	11	21	treatment	treatment	NN
cord-352096-cc3dzycl	11	22	,	,	,
cord-352096-cc3dzycl	11	23	and	and	CC
cord-352096-cc3dzycl	11	24	the	the	DT
cord-352096-cc3dzycl	11	25	knowledge	knowledge	NN
cord-352096-cc3dzycl	11	26	that	that	WDT
cord-352096-cc3dzycl	11	27	combination	combination	NN
cord-352096-cc3dzycl	11	28	therapy	therapy	NN
cord-352096-cc3dzycl	11	29	can	can	MD
cord-352096-cc3dzycl	11	30	enhance	enhance	VB
cord-352096-cc3dzycl	11	31	efficacy	efficacy	NN
cord-352096-cc3dzycl	11	32	and	and	CC
cord-352096-cc3dzycl	11	33	prevent	prevent	VB
cord-352096-cc3dzycl	11	34	the	the	DT
cord-352096-cc3dzycl	11	35	emergence	emergence	NN
cord-352096-cc3dzycl	11	36	of	of	IN
cord-352096-cc3dzycl	11	37	drug	drug	NN
cord-352096-cc3dzycl	11	38	resistance	resistance	NN
cord-352096-cc3dzycl	11	39	.	.	.
cord-352096-cc3dzycl	12	1	Although	although	IN
cord-352096-cc3dzycl	12	2	drugs	drug	NNS
cord-352096-cc3dzycl	12	3	to	to	TO
cord-352096-cc3dzycl	12	4	modulate	modulate	VB
cord-352096-cc3dzycl	12	5	the	the	DT
cord-352096-cc3dzycl	12	6	late	late	JJ
cord-352096-cc3dzycl	12	7	immunopathological	immunopathological	JJ
cord-352096-cc3dzycl	12	8	complications	complication	NNS
cord-352096-cc3dzycl	12	9	are	be	VBP
cord-352096-cc3dzycl	12	10	also	also	RB
cord-352096-cc3dzycl	12	11	needed	need	VBN
cord-352096-cc3dzycl	12	12	,	,	,
cord-352096-cc3dzycl	12	13	only	only	RB
cord-352096-cc3dzycl	12	14	highly	highly	RB
cord-352096-cc3dzycl	12	15	active	active	JJ
cord-352096-cc3dzycl	12	16	antiviral	antiviral	JJ
cord-352096-cc3dzycl	12	17	drugs	drug	NNS
cord-352096-cc3dzycl	12	18	will	will	MD
cord-352096-cc3dzycl	12	19	be	be	VB
cord-352096-cc3dzycl	12	20	beneficial	beneficial	JJ
cord-352096-cc3dzycl	12	21	for	for	IN
cord-352096-cc3dzycl	12	22	prophylaxis	prophylaxis	NN
cord-352096-cc3dzycl	12	23	,	,	,
cord-352096-cc3dzycl	12	24	the	the	DT
cord-352096-cc3dzycl	12	25	treatment	treatment	NN
cord-352096-cc3dzycl	12	26	of	of	IN
cord-352096-cc3dzycl	12	27	early	early	JJ
cord-352096-cc3dzycl	12	28	disease	disease	NN
cord-352096-cc3dzycl	12	29	,	,	,
cord-352096-cc3dzycl	12	30	and	and	CC
cord-352096-cc3dzycl	12	31	perhaps	perhaps	RB
cord-352096-cc3dzycl	12	32	the	the	DT
cord-352096-cc3dzycl	12	33	reduction	reduction	NN
cord-352096-cc3dzycl	12	34	of	of	IN
cord-352096-cc3dzycl	12	35	transmissibility	transmissibility	NN
cord-352096-cc3dzycl	12	36	.	.	.
cord-352096-cc3dzycl	13	1	Remdesivir	Remdesivir	NNP
cord-352096-cc3dzycl	13	2	targets	target	VBZ
cord-352096-cc3dzycl	13	3	the	the	DT
cord-352096-cc3dzycl	13	4	viral	viral	JJ
cord-352096-cc3dzycl	13	5	RNA	rna	NN
cord-352096-cc3dzycl	13	6	-	-	HYPH
cord-352096-cc3dzycl	13	7	dependent	dependent	JJ
cord-352096-cc3dzycl	13	8	RNA	RNA	NNP
cord-352096-cc3dzycl	13	9	polymerase	polymerase	NN
cord-352096-cc3dzycl	13	10	(	(	-LRB-
cord-352096-cc3dzycl	13	11	RdRp	RdRp	NNP
cord-352096-cc3dzycl	13	12	)	)	-RRB-
cord-352096-cc3dzycl	13	13	,	,	,
cord-352096-cc3dzycl	13	14	and	and	CC
cord-352096-cc3dzycl	13	15	additional	additional	JJ
cord-352096-cc3dzycl	13	16	inhibitors	inhibitor	NNS
cord-352096-cc3dzycl	13	17	of	of	IN
cord-352096-cc3dzycl	13	18	that	that	DT
cord-352096-cc3dzycl	13	19	enzyme	enzyme	NN
cord-352096-cc3dzycl	13	20	are	be	VBP
cord-352096-cc3dzycl	13	21	in	in	IN
cord-352096-cc3dzycl	13	22	development	development	NN
cord-352096-cc3dzycl	13	23	,	,	,
cord-352096-cc3dzycl	13	24	as	as	IN
cord-352096-cc3dzycl	13	25	mentioned	mention	VBN
cord-352096-cc3dzycl	13	26	below	below	RB
cord-352096-cc3dzycl	13	27	.	.	.
cord-352096-cc3dzycl	14	1	As	as	IN
cord-352096-cc3dzycl	14	2	viral	viral	JJ
cord-352096-cc3dzycl	14	3	enzymes	enzyme	NNS
cord-352096-cc3dzycl	14	4	are	be	VBP
cord-352096-cc3dzycl	14	5	critical	critical	JJ
cord-352096-cc3dzycl	14	6	for	for	IN
cord-352096-cc3dzycl	14	7	replication	replication	NN
cord-352096-cc3dzycl	14	8	and	and	CC
cord-352096-cc3dzycl	14	9	represent	represent	VB
cord-352096-cc3dzycl	14	10	the	the	DT
cord-352096-cc3dzycl	14	11	majority	majority	NN
cord-352096-cc3dzycl	14	12	of	of	IN
cord-352096-cc3dzycl	14	13	targets	target	NNS
cord-352096-cc3dzycl	14	14	of	of	IN
cord-352096-cc3dzycl	14	15	all	all	DT
cord-352096-cc3dzycl	14	16	approved	approve	VBN
cord-352096-cc3dzycl	14	17	antiviral	antiviral	JJ
cord-352096-cc3dzycl	14	18	drugs	drug	NNS
cord-352096-cc3dzycl	14	19	,	,	,
cord-352096-cc3dzycl	14	20	other	other	JJ
cord-352096-cc3dzycl	14	21	coronavirus	coronavirus	NN
cord-352096-cc3dzycl	14	22	enzymes	enzyme	NNS
cord-352096-cc3dzycl	14	23	represent	represent	VBP
cord-352096-cc3dzycl	14	24	obvious	obvious	JJ
cord-352096-cc3dzycl	14	25	candidate	candidate	NN
cord-352096-cc3dzycl	14	26	targets	target	NNS
cord-352096-cc3dzycl	14	27	for	for	IN
cord-352096-cc3dzycl	14	28	effective	effective	JJ
cord-352096-cc3dzycl	14	29	drugs	drug	NNS
cord-352096-cc3dzycl	14	30	.	.	.
cord-352096-cc3dzycl	15	1	With	with	IN
cord-352096-cc3dzycl	15	2	protease	protease	NN
cord-352096-cc3dzycl	15	3	inhibitors	inhibitor	NNS
cord-352096-cc3dzycl	15	4	proven	prove	VBN
cord-352096-cc3dzycl	15	5	as	as	IN
cord-352096-cc3dzycl	15	6	effective	effective	JJ
cord-352096-cc3dzycl	15	7	for	for	IN
cord-352096-cc3dzycl	15	8	antivirals	antiviral	NNS
cord-352096-cc3dzycl	15	9	against	against	IN
cord-352096-cc3dzycl	15	10	HIV	HIV	NNP
cord-352096-cc3dzycl	15	11	and	and	CC
cord-352096-cc3dzycl	15	12	hepatitis	hepatitis	NNP
cord-352096-cc3dzycl	15	13	C	C	NNP
cord-352096-cc3dzycl	15	14	virus	virus	NN
cord-352096-cc3dzycl	15	15	(	(	-LRB-
cord-352096-cc3dzycl	15	16	HCV	HCV	NNP
cord-352096-cc3dzycl	15	17	)	)	-RRB-
cord-352096-cc3dzycl	15	18	,	,	,
cord-352096-cc3dzycl	15	19	the	the	DT
cord-352096-cc3dzycl	15	20	two	two	CD
cord-352096-cc3dzycl	15	21	coronavirus	coronavirus	NN
cord-352096-cc3dzycl	15	22	proteases	protease	NNS
cord-352096-cc3dzycl	15	23	,	,	,
cord-352096-cc3dzycl	15	24	the	the	DT
cord-352096-cc3dzycl	15	25	main	main	JJ
cord-352096-cc3dzycl	15	26	protease	protease	NN
cord-352096-cc3dzycl	15	27	(	(	-LRB-
cord-352096-cc3dzycl	15	28	M	M	NNP
cord-352096-cc3dzycl	15	29	pro	pro	FW
cord-352096-cc3dzycl	15	30	)	)	-RRB-
cord-352096-cc3dzycl	15	31	and	and	CC
cord-352096-cc3dzycl	15	32	the	the	DT
cord-352096-cc3dzycl	15	33	papain	papain	NN
cord-352096-cc3dzycl	15	34	-	-	HYPH
cord-352096-cc3dzycl	15	35	like	like	JJ
cord-352096-cc3dzycl	15	36	protease	protease	NN
cord-352096-cc3dzycl	15	37	(	(	-LRB-
cord-352096-cc3dzycl	15	38	PL	pl	NN
cord-352096-cc3dzycl	15	39	pro	pro	FW
cord-352096-cc3dzycl	15	40	)	)	-RRB-
cord-352096-cc3dzycl	15	41	,	,	,
cord-352096-cc3dzycl	15	42	also	also	RB
cord-352096-cc3dzycl	15	43	stand	stand	VB
cord-352096-cc3dzycl	15	44	out	out	RP
cord-352096-cc3dzycl	15	45	as	as	IN
cord-352096-cc3dzycl	15	46	clear	clear	JJ
cord-352096-cc3dzycl	15	47	candidate	candidate	NN
cord-352096-cc3dzycl	15	48	targets	target	NNS
cord-352096-cc3dzycl	15	49	for	for	IN
cord-352096-cc3dzycl	15	50	antiviral	antiviral	JJ
cord-352096-cc3dzycl	15	51	drug	drug	NN
cord-352096-cc3dzycl	15	52	discovery	discovery	NN
cord-352096-cc3dzycl	15	53	.	.	.
cord-352096-cc3dzycl	16	1	Hattori	Hattori	NNP
cord-352096-cc3dzycl	16	2	et	et	NNP
cord-352096-cc3dzycl	16	3	al	al	NNP
cord-352096-cc3dzycl	16	4	.	.	.
cord-352096-cc3dzycl	17	1	(	(	-LRB-
cord-352096-cc3dzycl	17	2	1	1	LS
cord-352096-cc3dzycl	17	3	)	)	-RRB-
cord-352096-cc3dzycl	17	4	examined	examine	VBD
cord-352096-cc3dzycl	17	5	two	two	CD
cord-352096-cc3dzycl	17	6	indole	indole	NN
cord-352096-cc3dzycl	17	7	-	-	HYPH
cord-352096-cc3dzycl	17	8	chloropyridinyl	chloropyridinyl	NN
cord-352096-cc3dzycl	17	9	-	-	HYPH
cord-352096-cc3dzycl	17	10	ester	ester	NN
cord-352096-cc3dzycl	17	11	derivatives	derivative	NNS
cord-352096-cc3dzycl	17	12	,	,	,
cord-352096-cc3dzycl	17	13	GRL-0820	GRL-0820	NNP
cord-352096-cc3dzycl	17	14	and	and	CC
cord-352096-cc3dzycl	17	15	GRL-0920	GRL-0920	NNP
cord-352096-cc3dzycl	17	16	,	,	,
cord-352096-cc3dzycl	17	17	which	which	WDT
cord-352096-cc3dzycl	17	18	they	-PRON-	PRP
cord-352096-cc3dzycl	17	19	had	have	VBD
cord-352096-cc3dzycl	17	20	designed	design	VBN
cord-352096-cc3dzycl	17	21	against	against	IN
cord-352096-cc3dzycl	17	22	SARS	SARS	NNP
cord-352096-cc3dzycl	17	23	-	-	HYPH
cord-352096-cc3dzycl	17	24	CoV	CoV	NNP
cord-352096-cc3dzycl	17	25	before	before	IN
cord-352096-cc3dzycl	17	26	the	the	DT
cord-352096-cc3dzycl	17	27	emergence	emergence	NN
cord-352096-cc3dzycl	17	28	of	of	IN
cord-352096-cc3dzycl	17	29	SARS	SARS	NNP
cord-352096-cc3dzycl	17	30	-	-	HYPH
cord-352096-cc3dzycl	17	31	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	17	32	.	.	.
cord-352096-cc3dzycl	18	1	The	the	DT
cord-352096-cc3dzycl	18	2	M	M	NNP
cord-352096-cc3dzycl	18	3	pro	pro	NN
cord-352096-cc3dzycl	18	4	s	s	NNP
cord-352096-cc3dzycl	18	5	of	of	IN
cord-352096-cc3dzycl	18	6	the	the	DT
cord-352096-cc3dzycl	18	7	two	two	CD
cord-352096-cc3dzycl	18	8	viruses	virus	NNS
cord-352096-cc3dzycl	18	9	share	share	VBP
cord-352096-cc3dzycl	18	10	significant	significant	JJ
cord-352096-cc3dzycl	18	11	sequence	sequence	NN
cord-352096-cc3dzycl	18	12	and	and	CC
cord-352096-cc3dzycl	18	13	structural	structural	JJ
cord-352096-cc3dzycl	18	14	similarities	similarity	NNS
cord-352096-cc3dzycl	18	15	.	.	.
cord-352096-cc3dzycl	19	1	To	to	IN
cord-352096-cc3dzycl	19	2	their	-PRON-	PRP$
cord-352096-cc3dzycl	19	3	credit	credit	NN
cord-352096-cc3dzycl	19	4	,	,	,
cord-352096-cc3dzycl	19	5	Hattori	Hattori	NNP
cord-352096-cc3dzycl	19	6	et	et	NNP
cord-352096-cc3dzycl	19	7	al	al	NNP
cord-352096-cc3dzycl	19	8	.	.	.
cord-352096-cc3dzycl	20	1	use	use	VB
cord-352096-cc3dzycl	20	2	multiple	multiple	JJ
cord-352096-cc3dzycl	20	3	assays	assay	NNS
cord-352096-cc3dzycl	20	4	to	to	TO
cord-352096-cc3dzycl	20	5	document	document	VB
cord-352096-cc3dzycl	20	6	activity	activity	NN
cord-352096-cc3dzycl	20	7	(	(	-LRB-
cord-352096-cc3dzycl	20	8	inhibition	inhibition	NN
cord-352096-cc3dzycl	20	9	of	of	IN
cord-352096-cc3dzycl	20	10	infectivity	infectivity	NN
cord-352096-cc3dzycl	20	11	,	,	,
cord-352096-cc3dzycl	20	12	replication	replication	NN
cord-352096-cc3dzycl	20	13	,	,	,
cord-352096-cc3dzycl	20	14	and	and	CC
cord-352096-cc3dzycl	20	15	cytopathic	cytopathic	JJ
cord-352096-cc3dzycl	20	16	effects	effect	NNS
cord-352096-cc3dzycl	20	17	)	)	-RRB-
cord-352096-cc3dzycl	20	18	in	in	IN
cord-352096-cc3dzycl	20	19	two	two	CD
cord-352096-cc3dzycl	20	20	different	different	JJ
cord-352096-cc3dzycl	20	21	cell	cell	NN
cord-352096-cc3dzycl	20	22	lines	line	NNS
cord-352096-cc3dzycl	20	23	,	,	,
cord-352096-cc3dzycl	20	24	and	and	CC
cord-352096-cc3dzycl	20	25	importantly	importantly	RB
cord-352096-cc3dzycl	20	26	,	,	,
cord-352096-cc3dzycl	20	27	they	-PRON-	PRP
cord-352096-cc3dzycl	20	28	conscientiously	conscientiously	RB
cord-352096-cc3dzycl	20	29	characterize	characterize	VBP
cord-352096-cc3dzycl	20	30	cellular	cellular	JJ
cord-352096-cc3dzycl	20	31	toxicity	toxicity	NN
cord-352096-cc3dzycl	20	32	.	.	.
cord-352096-cc3dzycl	21	1	Too	too	RB
cord-352096-cc3dzycl	21	2	many	many	JJ
cord-352096-cc3dzycl	21	3	publica	publica	JJ
cord-352096-cc3dzycl	21	4	-	-	HYPH
cord-352096-cc3dzycl	21	5	tions	tion	NNS
cord-352096-cc3dzycl	21	6	fail	fail	VBP
cord-352096-cc3dzycl	21	7	to	to	TO
cord-352096-cc3dzycl	21	8	carefully	carefully	RB
cord-352096-cc3dzycl	21	9	recognize	recognize	VB
cord-352096-cc3dzycl	21	10	that	that	IN
cord-352096-cc3dzycl	21	11	the	the	DT
cord-352096-cc3dzycl	21	12	reduction	reduction	NN
cord-352096-cc3dzycl	21	13	of	of	IN
cord-352096-cc3dzycl	21	14	replication	replication	NN
cord-352096-cc3dzycl	21	15	that	that	WDT
cord-352096-cc3dzycl	21	16	is	be	VBZ
cord-352096-cc3dzycl	21	17	being	be	VBG
cord-352096-cc3dzycl	21	18	measured	measure	VBN
cord-352096-cc3dzycl	21	19	may	may	MD
cord-352096-cc3dzycl	21	20	be	be	VB
cord-352096-cc3dzycl	21	21	attributable	attributable	JJ
cord-352096-cc3dzycl	21	22	to	to	IN
cord-352096-cc3dzycl	21	23	diminished	diminished	JJ
cord-352096-cc3dzycl	21	24	host	host	NN
cord-352096-cc3dzycl	21	25	cell	cell	NN
cord-352096-cc3dzycl	21	26	viability	viability	NN
cord-352096-cc3dzycl	21	27	.	.	.
cord-352096-cc3dzycl	22	1	In	in	IN
cord-352096-cc3dzycl	22	2	fact	fact	NN
cord-352096-cc3dzycl	22	3	,	,	,
cord-352096-cc3dzycl	22	4	the	the	DT
cord-352096-cc3dzycl	22	5	data	datum	NNS
cord-352096-cc3dzycl	22	6	in	in	IN
cord-352096-cc3dzycl	22	7	the	the	DT
cord-352096-cc3dzycl	22	8	work	work	NN
cord-352096-cc3dzycl	22	9	of	of	IN
cord-352096-cc3dzycl	22	10	Hattori	Hattori	NNP
cord-352096-cc3dzycl	22	11	et	et	NNP
cord-352096-cc3dzycl	22	12	al	al	NNP
cord-352096-cc3dzycl	22	13	.	.	NNP
cord-352096-cc3dzycl	22	14	suggest	suggest	VB
cord-352096-cc3dzycl	22	15	that	that	IN
cord-352096-cc3dzycl	22	16	the	the	DT
cord-352096-cc3dzycl	22	17	purported	purported	JJ
cord-352096-cc3dzycl	22	18	activity	activity	NN
cord-352096-cc3dzycl	22	19	against	against	IN
cord-352096-cc3dzycl	22	20	SARS	SARS	NNP
cord-352096-cc3dzycl	22	21	-	-	HYPH
cord-352096-cc3dzycl	22	22	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	22	23	of	of	IN
cord-352096-cc3dzycl	22	24	the	the	DT
cord-352096-cc3dzycl	22	25	two	two	CD
cord-352096-cc3dzycl	22	26	HIV	HIV	NNP
cord-352096-cc3dzycl	22	27	protease	protease	NN
cord-352096-cc3dzycl	22	28	inhibitors	inhibitor	NNS
cord-352096-cc3dzycl	22	29	,	,	,
cord-352096-cc3dzycl	22	30	lopinavir	lopinavir	NNS
cord-352096-cc3dzycl	22	31	and	and	CC
cord-352096-cc3dzycl	22	32	nelfinavir	nelfinavir	NNP
cord-352096-cc3dzycl	22	33	,	,	,
cord-352096-cc3dzycl	22	34	is	be	VBZ
cord-352096-cc3dzycl	22	35	probably	probably	RB
cord-352096-cc3dzycl	22	36	attributable	attributable	JJ
cord-352096-cc3dzycl	22	37	to	to	IN
cord-352096-cc3dzycl	22	38	cellular	cellular	JJ
cord-352096-cc3dzycl	22	39	toxicity	toxicity	NN
cord-352096-cc3dzycl	22	40	.	.	.
cord-352096-cc3dzycl	23	1	Moreover	moreover	RB
cord-352096-cc3dzycl	23	2	,	,	,
cord-352096-cc3dzycl	23	3	the	the	DT
cord-352096-cc3dzycl	23	4	claims	claim	NNS
cord-352096-cc3dzycl	23	5	of	of	IN
cord-352096-cc3dzycl	23	6	activity	activity	NN
cord-352096-cc3dzycl	23	7	for	for	IN
cord-352096-cc3dzycl	23	8	chloroquine	chloroquine	NN
cord-352096-cc3dzycl	23	9	and	and	CC
cord-352096-cc3dzycl	23	10	hydroxychloroquine	hydroxychloroquine	NN
cord-352096-cc3dzycl	23	11	may	may	MD
cord-352096-cc3dzycl	23	12	be	be	VB
cord-352096-cc3dzycl	23	13	attributable	attributable	JJ
cord-352096-cc3dzycl	23	14	to	to	IN
cord-352096-cc3dzycl	23	15	cellular	cellular	JJ
cord-352096-cc3dzycl	23	16	toxicity	toxicity	NN
cord-352096-cc3dzycl	23	17	according	accord	VBG
cord-352096-cc3dzycl	23	18	to	to	IN
cord-352096-cc3dzycl	23	19	the	the	DT
cord-352096-cc3dzycl	23	20	data	datum	NNS
cord-352096-cc3dzycl	23	21	in	in	IN
cord-352096-cc3dzycl	23	22	the	the	DT
cord-352096-cc3dzycl	23	23	work	work	NN
cord-352096-cc3dzycl	23	24	of	of	IN
cord-352096-cc3dzycl	23	25	Hattori	Hattori	NNP
cord-352096-cc3dzycl	23	26	et	et	NNP
cord-352096-cc3dzycl	23	27	al	al	NNP
cord-352096-cc3dzycl	23	28	.	.	.
cord-352096-cc3dzycl	24	1	They	-PRON-	PRP
cord-352096-cc3dzycl	24	2	also	also	RB
cord-352096-cc3dzycl	24	3	confirm	confirm	VBP
cord-352096-cc3dzycl	24	4	with	with	IN
cord-352096-cc3dzycl	24	5	structural	structural	JJ
cord-352096-cc3dzycl	24	6	modeling	modeling	NN
cord-352096-cc3dzycl	24	7	and	and	CC
cord-352096-cc3dzycl	24	8	high	high	JJ
cord-352096-cc3dzycl	24	9	-	-	HYPH
cord-352096-cc3dzycl	24	10	performance	performance	NN
cord-352096-cc3dzycl	24	11	liquid	liquid	NN
cord-352096-cc3dzycl	24	12	chromatography	chromatography	NN
cord-352096-cc3dzycl	24	13	and	and	CC
cord-352096-cc3dzycl	24	14	mass	mass	NN
cord-352096-cc3dzycl	24	15	spectrometry	spectrometry	NN
cord-352096-cc3dzycl	24	16	(	(	-LRB-
cord-352096-cc3dzycl	24	17	HPLC	HPLC	NNP
cord-352096-cc3dzycl	24	18	/	/	SYM
cord-352096-cc3dzycl	24	19	MS	MS	NNP
cord-352096-cc3dzycl	24	20	)	)	-RRB-
cord-352096-cc3dzycl	24	21	that	that	IN
cord-352096-cc3dzycl	24	22	their	-PRON-	PRP$
cord-352096-cc3dzycl	24	23	inhibitors	inhibitor	NNS
cord-352096-cc3dzycl	24	24	of	of	IN
cord-352096-cc3dzycl	24	25	M	M	NNP
cord-352096-cc3dzycl	24	26	pro	pro	JJ
cord-352096-cc3dzycl	24	27	dock	dock	NN
cord-352096-cc3dzycl	24	28	and	and	CC
cord-352096-cc3dzycl	24	29	then	then	RB
cord-352096-cc3dzycl	24	30	covalently	covalently	RB
cord-352096-cc3dzycl	24	31	bind	bind	VB
cord-352096-cc3dzycl	24	32	in	in	IN
cord-352096-cc3dzycl	24	33	the	the	DT
cord-352096-cc3dzycl	24	34	catalytic	catalytic	JJ
cord-352096-cc3dzycl	24	35	site	site	NN
cord-352096-cc3dzycl	24	36	.	.	.
cord-352096-cc3dzycl	25	1	This	this	DT
cord-352096-cc3dzycl	25	2	information	information	NN
cord-352096-cc3dzycl	25	3	will	will	MD
cord-352096-cc3dzycl	25	4	provide	provide	VB
cord-352096-cc3dzycl	25	5	invaluable	invaluable	JJ
cord-352096-cc3dzycl	25	6	guidance	guidance	NN
cord-352096-cc3dzycl	25	7	for	for	IN
cord-352096-cc3dzycl	25	8	the	the	DT
cord-352096-cc3dzycl	25	9	modification	modification	NN
cord-352096-cc3dzycl	25	10	of	of	IN
cord-352096-cc3dzycl	25	11	the	the	DT
cord-352096-cc3dzycl	25	12	inhibitors	inhibitor	NNS
cord-352096-cc3dzycl	25	13	when	when	WRB
cord-352096-cc3dzycl	25	14	designing	design	VBG
cord-352096-cc3dzycl	25	15	yet	yet	RB
cord-352096-cc3dzycl	25	16	more	more	RBR
cord-352096-cc3dzycl	25	17	potent	potent	JJ
cord-352096-cc3dzycl	25	18	derivatives	derivative	NNS
cord-352096-cc3dzycl	25	19	.	.	.
cord-352096-cc3dzycl	26	1	In	in	IN
cord-352096-cc3dzycl	26	2	addition	addition	NN
cord-352096-cc3dzycl	26	3	to	to	IN
cord-352096-cc3dzycl	26	4	the	the	DT
cord-352096-cc3dzycl	26	5	identification	identification	NN
cord-352096-cc3dzycl	26	6	of	of	IN
cord-352096-cc3dzycl	26	7	compounds	compound	NNS
cord-352096-cc3dzycl	26	8	by	by	IN
cord-352096-cc3dzycl	26	9	Hattori	Hattori	NNP
cord-352096-cc3dzycl	26	10	et	et	NNP
cord-352096-cc3dzycl	26	11	al	al	NNP
cord-352096-cc3dzycl	26	12	.	.	.
cord-352096-cc3dzycl	27	1	Of	of	IN
cord-352096-cc3dzycl	27	2	note	note	NN
cord-352096-cc3dzycl	27	3	,	,	,
cord-352096-cc3dzycl	27	4	Hattori	Hattori	NNP
cord-352096-cc3dzycl	27	5	et	et	NNP
cord-352096-cc3dzycl	27	6	al	al	NNP
cord-352096-cc3dzycl	27	7	.	.	.
cord-352096-cc3dzycl	28	1	(	(	-LRB-
cord-352096-cc3dzycl	28	2	1	1	LS
cord-352096-cc3dzycl	28	3	)	)	-RRB-
cord-352096-cc3dzycl	28	4	found	find	VBD
cord-352096-cc3dzycl	28	5	no	no	DT
cord-352096-cc3dzycl	28	6	significant	significant	JJ
cord-352096-cc3dzycl	28	7	anti	anti	JJ
cord-352096-cc3dzycl	28	8	-	-	JJ
cord-352096-cc3dzycl	28	9	SARS	SARS	NNP
cord-352096-cc3dzycl	28	10	-	-	HYPH
cord-352096-cc3dzycl	28	11	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	28	12	activity	activity	NN
cord-352096-cc3dzycl	28	13	for	for	IN
cord-352096-cc3dzycl	28	14	several	several	JJ
cord-352096-cc3dzycl	28	15	compounds	compound	NNS
cord-352096-cc3dzycl	28	16	reportedly	reportedly	RB
cord-352096-cc3dzycl	28	17	active	active	JJ
cord-352096-cc3dzycl	28	18	against	against	IN
cord-352096-cc3dzycl	28	19	SARS	SARS	NNP
cord-352096-cc3dzycl	28	20	-	-	HYPH
cord-352096-cc3dzycl	28	21	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	28	22	,	,	,
cord-352096-cc3dzycl	28	23	including	include	VBG
cord-352096-cc3dzycl	28	24	lopinavir	lopinavir	NNS
cord-352096-cc3dzycl	28	25	,	,	,
cord-352096-cc3dzycl	28	26	nelfinavir	nelfinavir	NNP
cord-352096-cc3dzycl	28	27	,	,	,
cord-352096-cc3dzycl	28	28	nitazoxanide	nitazoxanide	NNP
cord-352096-cc3dzycl	28	29	,	,	,
cord-352096-cc3dzycl	28	30	favipiravir	favipiravir	NNP
cord-352096-cc3dzycl	28	31	,	,	,
cord-352096-cc3dzycl	28	32	and	and	CC
cord-352096-cc3dzycl	28	33	hydroxychloroquine	hydroxychloroquine	NNP
cord-352096-cc3dzycl	28	34	,	,	,
cord-352096-cc3dzycl	28	35	while	while	IN
cord-352096-cc3dzycl	28	36	the	the	DT
cord-352096-cc3dzycl	28	37	proven	prove	VBN
cord-352096-cc3dzycl	28	38	drug	drug	NN
cord-352096-cc3dzycl	28	39	remdesivir	remdesivir	NNP
cord-352096-cc3dzycl	28	40	displayed	display	VBD
cord-352096-cc3dzycl	28	41	activity	activity	NN
cord-352096-cc3dzycl	28	42	at	at	IN
cord-352096-cc3dzycl	28	43	nontoxic	nontoxic	JJ
cord-352096-cc3dzycl	28	44	concentrations	concentration	NNS
cord-352096-cc3dzycl	28	45	.	.	.
cord-352096-cc3dzycl	29	1	It	-PRON-	PRP
cord-352096-cc3dzycl	29	2	has	have	VBZ
cord-352096-cc3dzycl	29	3	been	be	VBN
cord-352096-cc3dzycl	29	4	frustrating	frustrating	JJ
cord-352096-cc3dzycl	29	5	to	to	TO
cord-352096-cc3dzycl	29	6	observe	observe	VB
cord-352096-cc3dzycl	29	7	the	the	DT
cord-352096-cc3dzycl	29	8	widespread	widespread	JJ
cord-352096-cc3dzycl	29	9	rush	rush	NN
cord-352096-cc3dzycl	29	10	to	to	TO
cord-352096-cc3dzycl	29	11	use	use	VB
cord-352096-cc3dzycl	29	12	these	these	DT
cord-352096-cc3dzycl	29	13	drugs	drug	NNS
cord-352096-cc3dzycl	29	14	both	both	DT
cord-352096-cc3dzycl	29	15	for	for	IN
cord-352096-cc3dzycl	29	16	patient	patient	JJ
cord-352096-cc3dzycl	29	17	management	management	NN
cord-352096-cc3dzycl	29	18	and	and	CC
cord-352096-cc3dzycl	29	19	in	in	IN
cord-352096-cc3dzycl	29	20	numerous	numerous	JJ
cord-352096-cc3dzycl	29	21	redundant	redundant	JJ
cord-352096-cc3dzycl	29	22	clinical	clinical	JJ
cord-352096-cc3dzycl	29	23	trials	trial	NNS
cord-352096-cc3dzycl	29	24	,	,	,
cord-352096-cc3dzycl	29	25	when	when	WRB
cord-352096-cc3dzycl	29	26	the	the	DT
cord-352096-cc3dzycl	29	27	in	in	FW
cord-352096-cc3dzycl	29	28	vitro	vitro	FW
cord-352096-cc3dzycl	29	29	data	datum	NNS
cord-352096-cc3dzycl	29	30	should	should	MD
cord-352096-cc3dzycl	29	31	be	be	VB
cord-352096-cc3dzycl	29	32	sufficient	sufficient	JJ
cord-352096-cc3dzycl	29	33	to	to	TO
cord-352096-cc3dzycl	29	34	discourage	discourage	VB
cord-352096-cc3dzycl	29	35	this	this	DT
cord-352096-cc3dzycl	29	36	enthusiasm	enthusiasm	NN
cord-352096-cc3dzycl	29	37	,	,	,
cord-352096-cc3dzycl	29	38	especially	especially	RB
cord-352096-cc3dzycl	29	39	when	when	WRB
cord-352096-cc3dzycl	29	40	their	-PRON-	PRP$
cord-352096-cc3dzycl	29	41	in	in	FW
cord-352096-cc3dzycl	29	42	vitro	vitro	FW
cord-352096-cc3dzycl	29	43	potency	potency	NN
cord-352096-cc3dzycl	29	44	against	against	IN
cord-352096-cc3dzycl	29	45	coronaviruses	coronaviruse	NNS
cord-352096-cc3dzycl	29	46	is	be	VBZ
cord-352096-cc3dzycl	29	47	so	so	RB
cord-352096-cc3dzycl	29	48	low	low	JJ
cord-352096-cc3dzycl	29	49	compared	compare	VBN
cord-352096-cc3dzycl	29	50	to	to	IN
cord-352096-cc3dzycl	29	51	their	-PRON-	PRP$
cord-352096-cc3dzycl	29	52	potency	potency	NN
cord-352096-cc3dzycl	29	53	against	against	IN
cord-352096-cc3dzycl	29	54	their	-PRON-	PRP$
cord-352096-cc3dzycl	29	55	proven	prove	VBN
cord-352096-cc3dzycl	29	56	targets	target	NNS
cord-352096-cc3dzycl	29	57	.	.	.
cord-352096-cc3dzycl	30	1	The	the	DT
cord-352096-cc3dzycl	30	2	urgency	urgency	NN
cord-352096-cc3dzycl	30	3	of	of	IN
cord-352096-cc3dzycl	30	4	curbing	curb	VBG
cord-352096-cc3dzycl	30	5	the	the	DT
cord-352096-cc3dzycl	30	6	COVID-19	COVID-19	NNP
cord-352096-cc3dzycl	30	7	pandemic	pandemic	NN
cord-352096-cc3dzycl	30	8	has	have	VBZ
cord-352096-cc3dzycl	30	9	motivated	motivate	VBN
cord-352096-cc3dzycl	30	10	a	a	DT
cord-352096-cc3dzycl	30	11	large	large	JJ
cord-352096-cc3dzycl	30	12	number	number	NN
cord-352096-cc3dzycl	30	13	of	of	IN
cord-352096-cc3dzycl	30	14	investigators	investigator	NNS
cord-352096-cc3dzycl	30	15	globally	globally	RB
cord-352096-cc3dzycl	30	16	to	to	TO
cord-352096-cc3dzycl	30	17	identify	identify	VB
cord-352096-cc3dzycl	30	18	new	new	JJ
cord-352096-cc3dzycl	30	19	drugs	drug	NNS
cord-352096-cc3dzycl	30	20	and	and	CC
cord-352096-cc3dzycl	30	21	repurpose	repurpose	VB
cord-352096-cc3dzycl	30	22	old	old	JJ
cord-352096-cc3dzycl	30	23	ones	one	NNS
cord-352096-cc3dzycl	30	24	to	to	TO
cord-352096-cc3dzycl	30	25	target	target	VB
cord-352096-cc3dzycl	30	26	viral	viral	JJ
cord-352096-cc3dzycl	30	27	proteins	protein	NNS
cord-352096-cc3dzycl	30	28	,	,	,
cord-352096-cc3dzycl	30	29	as	as	RB
cord-352096-cc3dzycl	30	30	well	well	RB
cord-352096-cc3dzycl	30	31	as	as	IN
cord-352096-cc3dzycl	30	32	some	some	DT
cord-352096-cc3dzycl	30	33	host	host	NN
cord-352096-cc3dzycl	30	34	cell	cell	NN
cord-352096-cc3dzycl	30	35	targets	target	NNS
cord-352096-cc3dzycl	30	36	essential	essential	JJ
cord-352096-cc3dzycl	30	37	for	for	IN
cord-352096-cc3dzycl	30	38	viral	viral	JJ
cord-352096-cc3dzycl	30	39	replication	replication	NN
cord-352096-cc3dzycl	30	40	.	.	.
cord-352096-cc3dzycl	31	1	The	the	DT
cord-352096-cc3dzycl	31	2	only	only	JJ
cord-352096-cc3dzycl	31	3	antiviral	antiviral	JJ
cord-352096-cc3dzycl	31	4	yet	yet	RB
cord-352096-cc3dzycl	31	5	shown	show	VBN
cord-352096-cc3dzycl	31	6	to	to	TO
cord-352096-cc3dzycl	31	7	have	have	VB
cord-352096-cc3dzycl	31	8	clinical	clinical	JJ
cord-352096-cc3dzycl	31	9	efficacy	efficacy	NN
cord-352096-cc3dzycl	31	10	is	be	VBZ
cord-352096-cc3dzycl	31	11	the	the	DT
cord-352096-cc3dzycl	31	12	RdRp	RdRp	NNP
cord-352096-cc3dzycl	31	13	inhibitor	inhibitor	NN
cord-352096-cc3dzycl	31	14	remdesivir	remdesivir	NNP
cord-352096-cc3dzycl	31	15	.	.	.
cord-352096-cc3dzycl	32	1	These	these	DT
cord-352096-cc3dzycl	32	2	studies	study	NNS
cord-352096-cc3dzycl	32	3	were	be	VBD
cord-352096-cc3dzycl	32	4	conducted	conduct	VBN
cord-352096-cc3dzycl	32	5	in	in	IN
cord-352096-cc3dzycl	32	6	subjects	subject	NNS
cord-352096-cc3dzycl	32	7	with	with	IN
cord-352096-cc3dzycl	32	8	moderate	moderate	JJ
cord-352096-cc3dzycl	32	9	to	to	IN
cord-352096-cc3dzycl	32	10	severe	severe	JJ
cord-352096-cc3dzycl	32	11	disease	disease	NN
cord-352096-cc3dzycl	32	12	,	,	,
cord-352096-cc3dzycl	32	13	while	while	IN
cord-352096-cc3dzycl	32	14	efficacy	efficacy	NN
cord-352096-cc3dzycl	32	15	with	with	IN
cord-352096-cc3dzycl	32	16	antiviral	antiviral	JJ
cord-352096-cc3dzycl	32	17	drugs	drug	NNS
cord-352096-cc3dzycl	32	18	generally	generally	RB
cord-352096-cc3dzycl	32	19	is	be	VBZ
cord-352096-cc3dzycl	32	20	greatest	great	JJS
cord-352096-cc3dzycl	32	21	when	when	WRB
cord-352096-cc3dzycl	32	22	administered	administer	VBN
cord-352096-cc3dzycl	32	23	early	early	RB
cord-352096-cc3dzycl	32	24	in	in	IN
cord-352096-cc3dzycl	32	25	disease	disease	NN
cord-352096-cc3dzycl	32	26	.	.	.
cord-352096-cc3dzycl	33	1	The	the	DT
cord-352096-cc3dzycl	33	2	results	result	NNS
cord-352096-cc3dzycl	33	3	of	of	IN
cord-352096-cc3dzycl	33	4	planned	plan	VBN
cord-352096-cc3dzycl	33	5	studies	study	NNS
cord-352096-cc3dzycl	33	6	with	with	IN
cord-352096-cc3dzycl	33	7	outpatient	outpatient	NNP
cord-352096-cc3dzycl	33	8	administration	administration	NN
cord-352096-cc3dzycl	33	9	to	to	IN
cord-352096-cc3dzycl	33	10	subjects	subject	NNS
cord-352096-cc3dzycl	33	11	at	at	IN
cord-352096-cc3dzycl	33	12	high	high	JJ
cord-352096-cc3dzycl	33	13	risk	risk	NN
cord-352096-cc3dzycl	33	14	for	for	IN
cord-352096-cc3dzycl	33	15	severe	severe	JJ
cord-352096-cc3dzycl	33	16	disease	disease	NN
cord-352096-cc3dzycl	33	17	,	,	,
cord-352096-cc3dzycl	33	18	of	of	IN
cord-352096-cc3dzycl	33	19	aerosolized	aerosolized	JJ
cord-352096-cc3dzycl	33	20	administration	administration	NN
cord-352096-cc3dzycl	33	21	,	,	,
cord-352096-cc3dzycl	33	22	and	and	CC
cord-352096-cc3dzycl	33	23	of	of	IN
cord-352096-cc3dzycl	33	24	remdesivir	remdesivir	NNP
cord-352096-cc3dzycl	33	25	in	in	IN
cord-352096-cc3dzycl	33	26	combination	combination	NN
cord-352096-cc3dzycl	33	27	with	with	IN
cord-352096-cc3dzycl	33	28	interferon	interferon	NNP
cord-352096-cc3dzycl	33	29	beta-1a	beta-1a	NNP
cord-352096-cc3dzycl	33	30	are	be	VBP
cord-352096-cc3dzycl	33	31	eagerly	eagerly	RB
cord-352096-cc3dzycl	33	32	awaited	await	VBN
cord-352096-cc3dzycl	33	33	.	.	.
cord-352096-cc3dzycl	34	1	Other	other	JJ
cord-352096-cc3dzycl	34	2	ribonucleoside	ribonucleoside	JJ
cord-352096-cc3dzycl	34	3	inhibitors	inhibitor	NNS
cord-352096-cc3dzycl	34	4	of	of	IN
cord-352096-cc3dzycl	34	5	RdRp	RdRp	NNP
cord-352096-cc3dzycl	34	6	,	,	,
cord-352096-cc3dzycl	34	7	which	which	WDT
cord-352096-cc3dzycl	34	8	are	be	VBP
cord-352096-cc3dzycl	34	9	orally	orally	RB
cord-352096-cc3dzycl	34	10	bioavailable	bioavailable	JJ
cord-352096-cc3dzycl	34	11	,	,	,
cord-352096-cc3dzycl	34	12	unlike	unlike	IN
cord-352096-cc3dzycl	34	13	remdesivir	remdesivir	NNP
cord-352096-cc3dzycl	34	14	,	,	,
cord-352096-cc3dzycl	34	15	have	have	VBP
cord-352096-cc3dzycl	34	16	entered	enter	VBN
cord-352096-cc3dzycl	34	17	clinical	clinical	JJ
cord-352096-cc3dzycl	34	18	trials	trial	NNS
cord-352096-cc3dzycl	34	19	.	.	.
cord-352096-cc3dzycl	35	1	MK-4482	MK-4482	NNP
cord-352096-cc3dzycl	35	2	(	(	-LRB-
cord-352096-cc3dzycl	35	3	formerly	formerly	RB
cord-352096-cc3dzycl	35	4	EIDD-2801	EIDD-2801	NNP
cord-352096-cc3dzycl	35	5	)	)	-RRB-
cord-352096-cc3dzycl	35	6	has	have	VBZ
cord-352096-cc3dzycl	35	7	activity	activity	NN
cord-352096-cc3dzycl	35	8	against	against	IN
cord-352096-cc3dzycl	35	9	SARS	SARS	NNP
cord-352096-cc3dzycl	35	10	-	-	HYPH
cord-352096-cc3dzycl	35	11	CoV	CoV	NNP
cord-352096-cc3dzycl	35	12	,	,	,
cord-352096-cc3dzycl	35	13	MERS	MERS	NNP
cord-352096-cc3dzycl	35	14	,	,	,
cord-352096-cc3dzycl	35	15	and	and	CC
cord-352096-cc3dzycl	35	16	SARS	SARS	NNP
cord-352096-cc3dzycl	35	17	-	-	HYPH
cord-352096-cc3dzycl	35	18	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	35	19	in	in	IN
cord-352096-cc3dzycl	35	20	mice	mouse	NNS
cord-352096-cc3dzycl	35	21	and	and	CC
cord-352096-cc3dzycl	35	22	is	be	VBZ
cord-352096-cc3dzycl	35	23	currently	currently	RB
cord-352096-cc3dzycl	35	24	being	be	VBG
cord-352096-cc3dzycl	35	25	studied	study	VBN
cord-352096-cc3dzycl	35	26	in	in	IN
cord-352096-cc3dzycl	35	27	humans	human	NNS
cord-352096-cc3dzycl	35	28	(	(	-LRB-
cord-352096-cc3dzycl	35	29	3	3	CD
cord-352096-cc3dzycl	35	30	)	)	-RRB-
cord-352096-cc3dzycl	35	31	.	.	.
cord-352096-cc3dzycl	36	1	MK-4482	MK-4482	NNP
cord-352096-cc3dzycl	36	2	appears	appear	VBZ
cord-352096-cc3dzycl	36	3	to	to	TO
cord-352096-cc3dzycl	36	4	act	act	VB
cord-352096-cc3dzycl	36	5	by	by	IN
cord-352096-cc3dzycl	36	6	inducing	induce	VBG
cord-352096-cc3dzycl	36	7	frequent	frequent	JJ
cord-352096-cc3dzycl	36	8	nucleoside	nucleoside	NN
cord-352096-cc3dzycl	36	9	transitions	transition	NNS
cord-352096-cc3dzycl	36	10	during	during	IN
cord-352096-cc3dzycl	36	11	RNA	RNA	NNP
cord-352096-cc3dzycl	36	12	replication	replication	NN
cord-352096-cc3dzycl	36	13	,	,	,
cord-352096-cc3dzycl	36	14	resulting	result	VBG
cord-352096-cc3dzycl	36	15	in	in	IN
cord-352096-cc3dzycl	36	16	increased	increase	VBN
cord-352096-cc3dzycl	36	17	error	error	NN
cord-352096-cc3dzycl	36	18	rates	rate	NNS
cord-352096-cc3dzycl	36	19	,	,	,
cord-352096-cc3dzycl	36	20	which	which	WDT
cord-352096-cc3dzycl	36	21	probably	probably	RB
cord-352096-cc3dzycl	36	22	account	account	VBP
cord-352096-cc3dzycl	36	23	for	for	IN
cord-352096-cc3dzycl	36	24	impaired	impaired	JJ
cord-352096-cc3dzycl	36	25	replication	replication	NN
cord-352096-cc3dzycl	36	26	.	.	.
cord-352096-cc3dzycl	37	1	AT-527	AT-527	NNP
cord-352096-cc3dzycl	37	2	is	be	VBZ
cord-352096-cc3dzycl	37	3	a	a	DT
cord-352096-cc3dzycl	37	4	prodrug	prodrug	NN
cord-352096-cc3dzycl	37	5	of	of	IN
cord-352096-cc3dzycl	37	6	a	a	DT
cord-352096-cc3dzycl	37	7	guanosine	guanosine	NN
cord-352096-cc3dzycl	37	8	ribonucleotide	ribonucleotide	NN
cord-352096-cc3dzycl	37	9	analog	analog	NN
cord-352096-cc3dzycl	37	10	,	,	,
cord-352096-cc3dzycl	37	11	which	which	WDT
cord-352096-cc3dzycl	37	12	was	be	VBD
cord-352096-cc3dzycl	37	13	well	well	RB
cord-352096-cc3dzycl	37	14	tolerated	tolerate	VBN
cord-352096-cc3dzycl	37	15	with	with	IN
cord-352096-cc3dzycl	37	16	substantial	substantial	JJ
cord-352096-cc3dzycl	37	17	activity	activity	NN
cord-352096-cc3dzycl	37	18	in	in	IN
cord-352096-cc3dzycl	37	19	studies	study	NNS
cord-352096-cc3dzycl	37	20	of	of	IN
cord-352096-cc3dzycl	37	21	HCV	HCV	NNP
cord-352096-cc3dzycl	37	22	-	-	HYPH
cord-352096-cc3dzycl	37	23	infected	infect	VBN
cord-352096-cc3dzycl	37	24	subjects	subject	NNS
cord-352096-cc3dzycl	37	25	(	(	-LRB-
cord-352096-cc3dzycl	37	26	4	4	CD
cord-352096-cc3dzycl	37	27	)	)	-RRB-
cord-352096-cc3dzycl	37	28	.	.	.
cord-352096-cc3dzycl	38	1	It	-PRON-	PRP
cord-352096-cc3dzycl	38	2	has	have	VBZ
cord-352096-cc3dzycl	38	3	in	in	IN
cord-352096-cc3dzycl	38	4	vitro	vitro	FW
cord-352096-cc3dzycl	38	5	activity	activity	NN
cord-352096-cc3dzycl	38	6	against	against	IN
cord-352096-cc3dzycl	38	7	SARS	SARS	NNP
cord-352096-cc3dzycl	38	8	-	-	HYPH
cord-352096-cc3dzycl	38	9	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	38	10	,	,	,
cord-352096-cc3dzycl	38	11	justifying	justify	VBG
cord-352096-cc3dzycl	38	12	its	-PRON-	PRP$
cord-352096-cc3dzycl	38	13	investigation	investigation	NN
cord-352096-cc3dzycl	38	14	for	for	IN
cord-352096-cc3dzycl	38	15	COVID-19	COVID-19	NNP
cord-352096-cc3dzycl	38	16	(	(	-LRB-
cord-352096-cc3dzycl	38	17	5	5	CD
cord-352096-cc3dzycl	38	18	)	)	-RRB-
cord-352096-cc3dzycl	38	19	.	.	.
cord-352096-cc3dzycl	39	1	Early	early	JJ
cord-352096-cc3dzycl	39	2	studies	study	NNS
cord-352096-cc3dzycl	39	3	with	with	IN
cord-352096-cc3dzycl	39	4	parenteral	parenteral	JJ
cord-352096-cc3dzycl	39	5	interferon	interferon	NN
cord-352096-cc3dzycl	39	6	beta-1b	beta-1b	NNP
cord-352096-cc3dzycl	39	7	(	(	-LRB-
cord-352096-cc3dzycl	39	8	6	6	CD
cord-352096-cc3dzycl	39	9	)	)	-RRB-
cord-352096-cc3dzycl	39	10	and	and	CC
cord-352096-cc3dzycl	39	11	inhaled	inhale	VBN
cord-352096-cc3dzycl	39	12	interferon	interferon	NN
cord-352096-cc3dzycl	39	13	beta	beta	NN
cord-352096-cc3dzycl	39	14	(	(	-LRB-
cord-352096-cc3dzycl	39	15	as	as	RB
cord-352096-cc3dzycl	39	16	yet	yet	RB
cord-352096-cc3dzycl	39	17	unpublished	unpublished	JJ
cord-352096-cc3dzycl	39	18	)	)	-RRB-
cord-352096-cc3dzycl	39	19	showed	show	VBD
cord-352096-cc3dzycl	39	20	encouraging	encouraging	JJ
cord-352096-cc3dzycl	39	21	results	result	NNS
cord-352096-cc3dzycl	39	22	.	.	.
cord-352096-cc3dzycl	40	1	Numerous	numerous	JJ
cord-352096-cc3dzycl	40	2	clinical	clinical	JJ
cord-352096-cc3dzycl	40	3	trials	trial	NNS
cord-352096-cc3dzycl	40	4	are	be	VBP
cord-352096-cc3dzycl	40	5	being	be	VBG
cord-352096-cc3dzycl	40	6	conducted	conduct	VBN
cord-352096-cc3dzycl	40	7	with	with	IN
cord-352096-cc3dzycl	40	8	specific	specific	JJ
cord-352096-cc3dzycl	40	9	antibodies	antibody	NNS
cord-352096-cc3dzycl	40	10	,	,	,
cord-352096-cc3dzycl	40	11	both	both	CC
cord-352096-cc3dzycl	40	12	from	from	IN
cord-352096-cc3dzycl	40	13	convalescent	convalescent	JJ
cord-352096-cc3dzycl	40	14	-	-	HYPH
cord-352096-cc3dzycl	40	15	phase	phase	NN
cord-352096-cc3dzycl	40	16	plasma	plasma	NN
cord-352096-cc3dzycl	40	17	and	and	CC
cord-352096-cc3dzycl	40	18	as	as	IN
cord-352096-cc3dzycl	40	19	monoclonal	monoclonal	JJ
cord-352096-cc3dzycl	40	20	antibody	antibody	NN
cord-352096-cc3dzycl	40	21	preparations	preparation	NNS
cord-352096-cc3dzycl	40	22	,	,	,
cord-352096-cc3dzycl	40	23	but	but	CC
cord-352096-cc3dzycl	40	24	no	no	DT
cord-352096-cc3dzycl	40	25	randomized	randomized	JJ
cord-352096-cc3dzycl	40	26	controlled	control	VBN
cord-352096-cc3dzycl	40	27	trials	trial	NNS
cord-352096-cc3dzycl	40	28	to	to	TO
cord-352096-cc3dzycl	40	29	document	document	NN
cord-352096-cc3dzycl	40	30	activity	activity	NN
cord-352096-cc3dzycl	40	31	clinically	clinically	RB
cord-352096-cc3dzycl	40	32	have	have	VBP
cord-352096-cc3dzycl	40	33	yet	yet	RB
cord-352096-cc3dzycl	40	34	been	be	VBN
cord-352096-cc3dzycl	40	35	published	publish	VBN
cord-352096-cc3dzycl	40	36	.	.	.
cord-352096-cc3dzycl	41	1	Repurposing	repurpose	VBG
cord-352096-cc3dzycl	41	2	already	already	RB
cord-352096-cc3dzycl	41	3	available	available	JJ
cord-352096-cc3dzycl	41	4	drugs	drug	NNS
cord-352096-cc3dzycl	41	5	is	be	VBZ
cord-352096-cc3dzycl	41	6	appealing	appeal	VBG
cord-352096-cc3dzycl	41	7	because	because	IN
cord-352096-cc3dzycl	41	8	the	the	DT
cord-352096-cc3dzycl	41	9	availability	availability	NN
cord-352096-cc3dzycl	41	10	of	of	IN
cord-352096-cc3dzycl	41	11	the	the	DT
cord-352096-cc3dzycl	41	12	drug	drug	NN
cord-352096-cc3dzycl	41	13	along	along	IN
cord-352096-cc3dzycl	41	14	with	with	IN
cord-352096-cc3dzycl	41	15	pharmacokinetic	pharmacokinetic	JJ
cord-352096-cc3dzycl	41	16	and	and	CC
cord-352096-cc3dzycl	41	17	toxicity	toxicity	NN
cord-352096-cc3dzycl	41	18	profiles	profile	NNS
cord-352096-cc3dzycl	41	19	facilitates	facilitate	VBZ
cord-352096-cc3dzycl	41	20	expeditious	expeditious	JJ
cord-352096-cc3dzycl	41	21	evaluation	evaluation	NN
cord-352096-cc3dzycl	41	22	for	for	IN
cord-352096-cc3dzycl	41	23	COVID-19	COVID-19	NNP
cord-352096-cc3dzycl	41	24	.	.	.
cord-352096-cc3dzycl	42	1	As	as	IN
cord-352096-cc3dzycl	42	2	mentioned	mention	VBN
cord-352096-cc3dzycl	42	3	above	above	RB
cord-352096-cc3dzycl	42	4	,	,	,
cord-352096-cc3dzycl	42	5	several	several	JJ
cord-352096-cc3dzycl	42	6	such	such	JJ
cord-352096-cc3dzycl	42	7	drugs	drug	NNS
cord-352096-cc3dzycl	42	8	have	have	VBP
cord-352096-cc3dzycl	42	9	been	be	VBN
cord-352096-cc3dzycl	42	10	and	and	CC
cord-352096-cc3dzycl	42	11	remain	remain	VB
cord-352096-cc3dzycl	42	12	under	under	IN
cord-352096-cc3dzycl	42	13	study	study	NN
cord-352096-cc3dzycl	42	14	because	because	IN
cord-352096-cc3dzycl	42	15	of	of	IN
cord-352096-cc3dzycl	42	16	ready	ready	JJ
cord-352096-cc3dzycl	42	17	availability	availability	NN
cord-352096-cc3dzycl	42	18	rather	rather	RB
cord-352096-cc3dzycl	42	19	than	than	IN
cord-352096-cc3dzycl	42	20	compelling	compel	VBG
cord-352096-cc3dzycl	42	21	in	in	IN
cord-352096-cc3dzycl	42	22	vitro	vitro	FW
cord-352096-cc3dzycl	42	23	activity	activity	NN
cord-352096-cc3dzycl	42	24	against	against	IN
cord-352096-cc3dzycl	42	25	SARS	SARS	NNP
cord-352096-cc3dzycl	42	26	-	-	HYPH
cord-352096-cc3dzycl	42	27	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	42	28	.	.	.
cord-352096-cc3dzycl	43	1	An	an	DT
cord-352096-cc3dzycl	43	2	exception	exception	NN
cord-352096-cc3dzycl	43	3	is	be	VBZ
cord-352096-cc3dzycl	43	4	camostat	camostat	NNP
cord-352096-cc3dzycl	43	5	mesylate	mesylate	NNP
cord-352096-cc3dzycl	43	6	,	,	,
cord-352096-cc3dzycl	43	7	which	which	WDT
cord-352096-cc3dzycl	43	8	has	have	VBZ
cord-352096-cc3dzycl	43	9	been	be	VBN
cord-352096-cc3dzycl	43	10	approved	approve	VBN
cord-352096-cc3dzycl	43	11	for	for	IN
cord-352096-cc3dzycl	43	12	the	the	DT
cord-352096-cc3dzycl	43	13	treatment	treatment	NN
cord-352096-cc3dzycl	43	14	of	of	IN
cord-352096-cc3dzycl	43	15	pancreatic	pancreatic	JJ
cord-352096-cc3dzycl	43	16	cancer	cancer	NN
cord-352096-cc3dzycl	43	17	in	in	IN
cord-352096-cc3dzycl	43	18	Japan	Japan	NNP
cord-352096-cc3dzycl	43	19	.	.	.
cord-352096-cc3dzycl	44	1	Camostat	Camostat	NNP
cord-352096-cc3dzycl	44	2	mesylate	mesylate	NNP
cord-352096-cc3dzycl	44	3	inhibits	inhibit	VBZ
cord-352096-cc3dzycl	44	4	the	the	DT
cord-352096-cc3dzycl	44	5	host	host	NN
cord-352096-cc3dzycl	44	6	serine	serine	NN
cord-352096-cc3dzycl	44	7	protease	protease	NNP
cord-352096-cc3dzycl	44	8	TMPRSS2	TMPRSS2	NNP
cord-352096-cc3dzycl	44	9	,	,	,
cord-352096-cc3dzycl	44	10	which	which	WDT
cord-352096-cc3dzycl	44	11	dramatically	dramatically	RB
cord-352096-cc3dzycl	44	12	enhances	enhance	VBZ
cord-352096-cc3dzycl	44	13	SARS	SARS	NNP
cord-352096-cc3dzycl	44	14	-	-	HYPH
cord-352096-cc3dzycl	44	15	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	44	16	replication	replication	NN
cord-352096-cc3dzycl	44	17	by	by	IN
cord-352096-cc3dzycl	44	18	proteolytically	proteolytically	RB
cord-352096-cc3dzycl	44	19	cleaving	cleave	VBG
cord-352096-cc3dzycl	44	20	the	the	DT
cord-352096-cc3dzycl	44	21	spike	spike	NN
cord-352096-cc3dzycl	44	22	(	(	-LRB-
cord-352096-cc3dzycl	44	23	S	s	NN
cord-352096-cc3dzycl	44	24	)	)	-RRB-
cord-352096-cc3dzycl	44	25	protein	protein	NN
cord-352096-cc3dzycl	44	26	of	of	IN
cord-352096-cc3dzycl	44	27	the	the	DT
cord-352096-cc3dzycl	44	28	virus	virus	NN
cord-352096-cc3dzycl	44	29	to	to	TO
cord-352096-cc3dzycl	44	30	activate	activate	VB
cord-352096-cc3dzycl	44	31	the	the	DT
cord-352096-cc3dzycl	44	32	spike	spike	NN
cord-352096-cc3dzycl	44	33	to	to	TO
cord-352096-cc3dzycl	44	34	mediate	mediate	VB
cord-352096-cc3dzycl	44	35	cell	cell	NN
cord-352096-cc3dzycl	44	36	entry	entry	NN
cord-352096-cc3dzycl	44	37	(	(	-LRB-
cord-352096-cc3dzycl	44	38	7	7	CD
cord-352096-cc3dzycl	44	39	)	)	-RRB-
cord-352096-cc3dzycl	44	40	.	.	.
cord-352096-cc3dzycl	45	1	With	with	IN
cord-352096-cc3dzycl	45	2	human	human	JJ
cord-352096-cc3dzycl	45	3	safety	safety	NN
cord-352096-cc3dzycl	45	4	and	and	CC
cord-352096-cc3dzycl	45	5	pharmacokinetics	pharmacokinetics	NNP
cord-352096-cc3dzycl	45	6	already	already	RB
cord-352096-cc3dzycl	45	7	characterized	characterize	VBD
cord-352096-cc3dzycl	45	8	,	,	,
cord-352096-cc3dzycl	45	9	camostat	camostat	NNP
cord-352096-cc3dzycl	45	10	mesylate	mesylate	NNP
cord-352096-cc3dzycl	45	11	is	be	VBZ
cord-352096-cc3dzycl	45	12	in	in	IN
cord-352096-cc3dzycl	45	13	several	several	JJ
cord-352096-cc3dzycl	45	14	clinical	clinical	JJ
cord-352096-cc3dzycl	45	15	trials	trial	NNS
cord-352096-cc3dzycl	45	16	as	as	IN
cord-352096-cc3dzycl	45	17	a	a	DT
cord-352096-cc3dzycl	45	18	repurposed	repurpose	VBN
cord-352096-cc3dzycl	45	19	drug	drug	NN
cord-352096-cc3dzycl	45	20	for	for	IN
cord-352096-cc3dzycl	45	21	COVID-19	COVID-19	NNP
cord-352096-cc3dzycl	45	22	.	.	.
cord-352096-cc3dzycl	46	1	The	the	DT
cord-352096-cc3dzycl	46	2	severe	severe	JJ
cord-352096-cc3dzycl	46	3	complications	complication	NNS
cord-352096-cc3dzycl	46	4	of	of	IN
cord-352096-cc3dzycl	46	5	COVID-19	COVID-19	NNP
cord-352096-cc3dzycl	46	6	appear	appear	VBP
cord-352096-cc3dzycl	46	7	to	to	TO
cord-352096-cc3dzycl	46	8	be	be	VB
cord-352096-cc3dzycl	46	9	more	more	JJR
cord-352096-cc3dzycl	46	10	the	the	DT
cord-352096-cc3dzycl	46	11	consequence	consequence	NN
cord-352096-cc3dzycl	46	12	of	of	IN
cord-352096-cc3dzycl	46	13	a	a	DT
cord-352096-cc3dzycl	46	14	misguided	misguided	JJ
cord-352096-cc3dzycl	46	15	,	,	,
cord-352096-cc3dzycl	46	16	pathological	pathological	JJ
cord-352096-cc3dzycl	46	17	host	host	NN
cord-352096-cc3dzycl	46	18	immune	immune	JJ
cord-352096-cc3dzycl	46	19	response	response	NN
cord-352096-cc3dzycl	46	20	to	to	IN
cord-352096-cc3dzycl	46	21	ongoing	ongoing	JJ
cord-352096-cc3dzycl	46	22	viral	viral	JJ
cord-352096-cc3dzycl	46	23	infection	infection	NN
cord-352096-cc3dzycl	46	24	(	(	-LRB-
cord-352096-cc3dzycl	46	25	8)	8)	NNP
cord-352096-cc3dzycl	46	26	.	.	.
cord-352096-cc3dzycl	47	1	Numerous	numerous	JJ
cord-352096-cc3dzycl	47	2	studies	study	NNS
cord-352096-cc3dzycl	47	3	are	be	VBP
cord-352096-cc3dzycl	47	4	in	in	IN
cord-352096-cc3dzycl	47	5	progress	progress	NN
cord-352096-cc3dzycl	47	6	to	to	TO
cord-352096-cc3dzycl	47	7	identify	identify	VB
cord-352096-cc3dzycl	47	8	effective	effective	JJ
cord-352096-cc3dzycl	47	9	modulators	modulator	NNS
cord-352096-cc3dzycl	47	10	of	of	IN
cord-352096-cc3dzycl	47	11	this	this	DT
cord-352096-cc3dzycl	47	12	dysregulated	dysregulate	VBN
cord-352096-cc3dzycl	47	13	immune	immune	JJ
cord-352096-cc3dzycl	47	14	response	response	NN
cord-352096-cc3dzycl	47	15	with	with	IN
cord-352096-cc3dzycl	47	16	some	some	DT
cord-352096-cc3dzycl	47	17	early	early	JJ
cord-352096-cc3dzycl	47	18	indications	indication	NNS
cord-352096-cc3dzycl	47	19	of	of	IN
cord-352096-cc3dzycl	47	20	efficacy	efficacy	NN
cord-352096-cc3dzycl	47	21	of	of	IN
cord-352096-cc3dzycl	47	22	the	the	DT
cord-352096-cc3dzycl	47	23	corticosteroid	corticosteroid	NN
cord-352096-cc3dzycl	47	24	dexa	dexa	NNP
cord-352096-cc3dzycl	47	25	-	-	HYPH
cord-352096-cc3dzycl	47	26	methasone	methasone	NNP
cord-352096-cc3dzycl	47	27	(	(	-LRB-
cord-352096-cc3dzycl	47	28	9	9	CD
cord-352096-cc3dzycl	47	29	)	)	-RRB-
cord-352096-cc3dzycl	47	30	.	.	.
cord-352096-cc3dzycl	48	1	The	the	DT
cord-352096-cc3dzycl	48	2	potential	potential	JJ
cord-352096-cc3dzycl	48	3	benefits	benefit	NNS
cord-352096-cc3dzycl	48	4	of	of	IN
cord-352096-cc3dzycl	48	5	inhibitors	inhibitor	NNS
cord-352096-cc3dzycl	48	6	of	of	IN
cord-352096-cc3dzycl	48	7	interleukin-6	interleukin-6	NNP
cord-352096-cc3dzycl	48	8	and	and	CC
cord-352096-cc3dzycl	48	9	other	other	JJ
cord-352096-cc3dzycl	48	10	cytokines	cytokine	NNS
cord-352096-cc3dzycl	48	11	and	and	CC
cord-352096-cc3dzycl	48	12	chemokines	chemokine	NNS
cord-352096-cc3dzycl	48	13	are	be	VBP
cord-352096-cc3dzycl	48	14	being	be	VBG
cord-352096-cc3dzycl	48	15	examined	examine	VBN
cord-352096-cc3dzycl	48	16	in	in	IN
cord-352096-cc3dzycl	48	17	multiple	multiple	JJ
cord-352096-cc3dzycl	48	18	clinical	clinical	JJ
cord-352096-cc3dzycl	48	19	trials	trial	NNS
cord-352096-cc3dzycl	48	20	,	,	,
cord-352096-cc3dzycl	48	21	but	but	CC
cord-352096-cc3dzycl	48	22	evidence	evidence	NN
cord-352096-cc3dzycl	48	23	of	of	IN
cord-352096-cc3dzycl	48	24	clinical	clinical	JJ
cord-352096-cc3dzycl	48	25	efficacy	efficacy	NN
cord-352096-cc3dzycl	48	26	is	be	VBZ
cord-352096-cc3dzycl	48	27	pending	pende	VBG
cord-352096-cc3dzycl	48	28	.	.	.
cord-352096-cc3dzycl	49	1	The	the	DT
cord-352096-cc3dzycl	49	2	Mitsuya	Mitsuya	NNP
cord-352096-cc3dzycl	49	3	group	group	NN
cord-352096-cc3dzycl	49	4	has	have	VBZ
cord-352096-cc3dzycl	49	5	a	a	DT
cord-352096-cc3dzycl	49	6	track	track	NN
cord-352096-cc3dzycl	49	7	record	record	NN
cord-352096-cc3dzycl	49	8	of	of	IN
cord-352096-cc3dzycl	49	9	developing	develop	VBG
cord-352096-cc3dzycl	49	10	drugs	drug	NNS
cord-352096-cc3dzycl	49	11	that	that	WDT
cord-352096-cc3dzycl	49	12	are	be	VBP
cord-352096-cc3dzycl	49	13	effective	effective	JJ
cord-352096-cc3dzycl	49	14	against	against	IN
cord-352096-cc3dzycl	49	15	HIV	HIV	NNP
cord-352096-cc3dzycl	49	16	infection	infection	NN
cord-352096-cc3dzycl	49	17	.	.	.
cord-352096-cc3dzycl	50	1	These	these	DT
cord-352096-cc3dzycl	50	2	include	include	VBP
cord-352096-cc3dzycl	50	3	the	the	DT
cord-352096-cc3dzycl	50	4	reverse	reverse	JJ
cord-352096-cc3dzycl	50	5	transcriptase	transcriptase	NN
cord-352096-cc3dzycl	50	6	inhibitors	inhibitor	NNS
cord-352096-cc3dzycl	50	7	ddC	ddc	VBP
cord-352096-cc3dzycl	50	8	(	(	-LRB-
cord-352096-cc3dzycl	50	9	zalcitabine	zalcitabine	NNP
cord-352096-cc3dzycl	50	10	)	)	-RRB-
cord-352096-cc3dzycl	50	11	and	and	CC
cord-352096-cc3dzycl	50	12	ddI	ddi	JJ
cord-352096-cc3dzycl	50	13	(	(	-LRB-
cord-352096-cc3dzycl	50	14	didanosine	didanosine	NNP
cord-352096-cc3dzycl	50	15	)	)	-RRB-
cord-352096-cc3dzycl	50	16	,	,	,
cord-352096-cc3dzycl	50	17	the	the	DT
cord-352096-cc3dzycl	50	18	protease	protease	NN
cord-352096-cc3dzycl	50	19	inhibitor	inhibitor	NN
cord-352096-cc3dzycl	50	20	darunavir	darunavir	NNP
cord-352096-cc3dzycl	50	21	,	,	,
cord-352096-cc3dzycl	50	22	and	and	CC
cord-352096-cc3dzycl	50	23	the	the	DT
cord-352096-cc3dzycl	50	24	reverse	reverse	JJ
cord-352096-cc3dzycl	50	25	transcriptase	transcriptase	NN
cord-352096-cc3dzycl	50	26	translocation	translocation	NN
cord-352096-cc3dzycl	50	27	inhibitor	inhibitor	NN
cord-352096-cc3dzycl	50	28	islatavir	islatavir	NNP
cord-352096-cc3dzycl	50	29	(	(	-LRB-
cord-352096-cc3dzycl	50	30	10	10	CD
cord-352096-cc3dzycl	50	31	)	)	-RRB-
cord-352096-cc3dzycl	50	32	(	(	-LRB-
cord-352096-cc3dzycl	50	33	11	11	CD
cord-352096-cc3dzycl	50	34	)	)	-RRB-
cord-352096-cc3dzycl	50	35	(	(	-LRB-
cord-352096-cc3dzycl	50	36	12	12	CD
cord-352096-cc3dzycl	50	37	)	)	-RRB-
cord-352096-cc3dzycl	50	38	.	.	.
cord-352096-cc3dzycl	51	1	With	with	IN
cord-352096-cc3dzycl	51	2	the	the	DT
cord-352096-cc3dzycl	51	3	need	need	NN
cord-352096-cc3dzycl	51	4	for	for	IN
cord-352096-cc3dzycl	51	5	antiviral	antiviral	JJ
cord-352096-cc3dzycl	51	6	drugs	drug	NNS
cord-352096-cc3dzycl	51	7	for	for	IN
cord-352096-cc3dzycl	51	8	COVID-19	COVID-19	NNP
cord-352096-cc3dzycl	51	9	,	,	,
cord-352096-cc3dzycl	51	10	we	-PRON-	PRP
cord-352096-cc3dzycl	51	11	can	can	MD
cord-352096-cc3dzycl	51	12	all	all	RB
cord-352096-cc3dzycl	51	13	hope	hope	VB
cord-352096-cc3dzycl	51	14	that	that	IN
cord-352096-cc3dzycl	51	15	not	not	RB
cord-352096-cc3dzycl	51	16	only	only	RB
cord-352096-cc3dzycl	51	17	will	will	MD
cord-352096-cc3dzycl	51	18	this	this	DT
cord-352096-cc3dzycl	51	19	group	group	NN
cord-352096-cc3dzycl	51	20	be	be	VB
cord-352096-cc3dzycl	51	21	successful	successful	JJ
cord-352096-cc3dzycl	51	22	in	in	IN
cord-352096-cc3dzycl	51	23	identifying	identify	VBG
cord-352096-cc3dzycl	51	24	effective	effective	JJ
cord-352096-cc3dzycl	51	25	coronavirus	coronavirus	NN
cord-352096-cc3dzycl	51	26	drugs	drug	NNS
cord-352096-cc3dzycl	51	27	,	,	,
cord-352096-cc3dzycl	51	28	but	but	CC
cord-352096-cc3dzycl	51	29	that	that	IN
cord-352096-cc3dzycl	51	30	numerous	numerous	JJ
cord-352096-cc3dzycl	51	31	other	other	JJ
cord-352096-cc3dzycl	51	32	investigators	investigator	NNS
cord-352096-cc3dzycl	51	33	are	be	VBP
cord-352096-cc3dzycl	51	34	successful	successful	JJ
cord-352096-cc3dzycl	51	35	in	in	IN
cord-352096-cc3dzycl	51	36	finding	find	VBG
cord-352096-cc3dzycl	51	37	drugs	drug	NNS
cord-352096-cc3dzycl	51	38	against	against	IN
cord-352096-cc3dzycl	51	39	multiple	multiple	JJ
cord-352096-cc3dzycl	51	40	targets	target	NNS
cord-352096-cc3dzycl	51	41	.	.	.
cord-352096-cc3dzycl	52	1	We	-PRON-	PRP
cord-352096-cc3dzycl	52	2	have	have	VBP
cord-352096-cc3dzycl	52	3	learned	learn	VBN
cord-352096-cc3dzycl	52	4	with	with	IN
cord-352096-cc3dzycl	52	5	other	other	JJ
cord-352096-cc3dzycl	52	6	viral	viral	JJ
cord-352096-cc3dzycl	52	7	diseases	disease	NNS
cord-352096-cc3dzycl	52	8	that	that	WDT
cord-352096-cc3dzycl	52	9	to	to	TO
cord-352096-cc3dzycl	52	10	address	address	VB
cord-352096-cc3dzycl	52	11	the	the	DT
cord-352096-cc3dzycl	52	12	challenges	challenge	NNS
cord-352096-cc3dzycl	52	13	of	of	IN
cord-352096-cc3dzycl	52	14	safety	safety	NN
cord-352096-cc3dzycl	52	15	,	,	,
cord-352096-cc3dzycl	52	16	efficacy	efficacy	NN
cord-352096-cc3dzycl	52	17	,	,	,
cord-352096-cc3dzycl	52	18	and	and	CC
cord-352096-cc3dzycl	52	19	drug	drug	NN
cord-352096-cc3dzycl	52	20	resistance	resistance	NN
cord-352096-cc3dzycl	52	21	,	,	,
cord-352096-cc3dzycl	52	22	to	to	TO
cord-352096-cc3dzycl	52	23	tackle	tackle	VB
cord-352096-cc3dzycl	52	24	the	the	DT
cord-352096-cc3dzycl	52	25	demands	demand	NNS
cord-352096-cc3dzycl	52	26	of	of	IN
cord-352096-cc3dzycl	52	27	both	both	DT
cord-352096-cc3dzycl	52	28	prophylaxis	prophylaxis	NN
cord-352096-cc3dzycl	52	29	and	and	CC
cord-352096-cc3dzycl	52	30	treatment	treatment	NN
cord-352096-cc3dzycl	52	31	,	,	,
cord-352096-cc3dzycl	52	32	and	and	CC
cord-352096-cc3dzycl	52	33	to	to	TO
cord-352096-cc3dzycl	52	34	manage	manage	VB
cord-352096-cc3dzycl	52	35	both	both	CC
cord-352096-cc3dzycl	52	36	the	the	DT
cord-352096-cc3dzycl	52	37	viral	viral	JJ
cord-352096-cc3dzycl	52	38	replication	replication	NN
cord-352096-cc3dzycl	52	39	and	and	CC
cord-352096-cc3dzycl	52	40	immunopathological	immunopathological	JJ
cord-352096-cc3dzycl	52	41	aspects	aspect	NNS
cord-352096-cc3dzycl	52	42	of	of	IN
cord-352096-cc3dzycl	52	43	COVID-19	COVID-19	NNP
cord-352096-cc3dzycl	52	44	,	,	,
cord-352096-cc3dzycl	52	45	numerous	numerous	JJ
cord-352096-cc3dzycl	52	46	drugs	drug	NNS
cord-352096-cc3dzycl	52	47	will	will	MD
cord-352096-cc3dzycl	52	48	be	be	VB
cord-352096-cc3dzycl	52	49	needed	need	VBN
cord-352096-cc3dzycl	52	50	.	.	.
cord-352096-cc3dzycl	53	1	Let	let	VB
cord-352096-cc3dzycl	53	2	us	-PRON-	PRP
cord-352096-cc3dzycl	53	3	all	all	DT
cord-352096-cc3dzycl	53	4	applaud	applaud	VB
cord-352096-cc3dzycl	53	5	the	the	DT
cord-352096-cc3dzycl	53	6	many	many	JJ
cord-352096-cc3dzycl	53	7	efforts	effort	NNS
cord-352096-cc3dzycl	53	8	and	and	CC
cord-352096-cc3dzycl	53	9	wish	wish	VB
cord-352096-cc3dzycl	53	10	many	many	JJ
cord-352096-cc3dzycl	53	11	successes	success	NNS
cord-352096-cc3dzycl	53	12	in	in	IN
cord-352096-cc3dzycl	53	13	the	the	DT
cord-352096-cc3dzycl	53	14	battle	battle	NN
cord-352096-cc3dzycl	53	15	against	against	IN
cord-352096-cc3dzycl	53	16	this	this	DT
cord-352096-cc3dzycl	53	17	pandemic	pandemic	NN
cord-352096-cc3dzycl	53	18	.	.	.
cord-352096-cc3dzycl	54	1	GRL-0920	GRL-0920	NNP
cord-352096-cc3dzycl	54	2	,	,	,
cord-352096-cc3dzycl	54	3	an	an	DT
cord-352096-cc3dzycl	54	4	indole	indole	NN
cord-352096-cc3dzycl	54	5	chloropyridinyl	chloropyridinyl	NN
cord-352096-cc3dzycl	54	6	ester	ester	NN
cord-352096-cc3dzycl	54	7	,	,	,
cord-352096-cc3dzycl	54	8	completely	completely	RB
cord-352096-cc3dzycl	54	9	blocks	block	VBZ
cord-352096-cc3dzycl	54	10	SARS	SARS	NNP
cord-352096-cc3dzycl	54	11	-	-	HYPH
cord-352096-cc3dzycl	54	12	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	54	13	infection	infection	NN
cord-352096-cc3dzycl	55	1	Structurebased	structurebased	JJ
cord-352096-cc3dzycl	55	2	design	design	NN
cord-352096-cc3dzycl	55	3	of	of	IN
cord-352096-cc3dzycl	55	4	antiviral	antiviral	JJ
cord-352096-cc3dzycl	55	5	drug	drug	NN
cord-352096-cc3dzycl	55	6	candidates	candidate	NNS
cord-352096-cc3dzycl	55	7	targeting	target	VBG
cord-352096-cc3dzycl	55	8	the	the	DT
cord-352096-cc3dzycl	55	9	SARS	SARS	NNP
cord-352096-cc3dzycl	55	10	-	-	HYPH
cord-352096-cc3dzycl	55	11	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	55	12	main	main	JJ
cord-352096-cc3dzycl	55	13	protease	protease	NN
cord-352096-cc3dzycl	56	1	An	an	DT
cord-352096-cc3dzycl	56	2	orally	orally	RB
cord-352096-cc3dzycl	56	3	bioavailable	bioavailable	JJ
cord-352096-cc3dzycl	56	4	broad	broad	JJ
cord-352096-cc3dzycl	56	5	-	-	HYPH
cord-352096-cc3dzycl	56	6	spectrum	spectrum	NN
cord-352096-cc3dzycl	56	7	antiviral	antiviral	JJ
cord-352096-cc3dzycl	56	8	inhibits	inhibit	VBZ
cord-352096-cc3dzycl	56	9	SARS	SARS	NNP
cord-352096-cc3dzycl	56	10	-	-	HYPH
cord-352096-cc3dzycl	56	11	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	56	12	in	in	IN
cord-352096-cc3dzycl	56	13	human	human	JJ
cord-352096-cc3dzycl	56	14	airway	airway	NN
cord-352096-cc3dzycl	56	15	epithelial	epithelial	JJ
cord-352096-cc3dzycl	56	16	cell	cell	NN
cord-352096-cc3dzycl	56	17	cultures	culture	NNS
cord-352096-cc3dzycl	56	18	and	and	CC
cord-352096-cc3dzycl	56	19	multiple	multiple	JJ
cord-352096-cc3dzycl	56	20	coronaviruses	coronaviruse	NNS
cord-352096-cc3dzycl	56	21	in	in	IN
cord-352096-cc3dzycl	56	22	mice	mouse	NNS
cord-352096-cc3dzycl	56	23	Safety	Safety	NNP
cord-352096-cc3dzycl	56	24	,	,	,
cord-352096-cc3dzycl	56	25	pharmacokinetics	pharmacokinetic	NNS
cord-352096-cc3dzycl	56	26	and	and	CC
cord-352096-cc3dzycl	56	27	antiviral	antiviral	JJ
cord-352096-cc3dzycl	56	28	activity	activity	NN
cord-352096-cc3dzycl	56	29	of	of	IN
cord-352096-cc3dzycl	56	30	AT-527	AT-527	NNP
cord-352096-cc3dzycl	56	31	,	,	,
cord-352096-cc3dzycl	56	32	a	a	DT
cord-352096-cc3dzycl	56	33	novel	novel	NN
cord-352096-cc3dzycl	56	34	purine	purine	NN
cord-352096-cc3dzycl	56	35	nucleotide	nucleotide	JJ
cord-352096-cc3dzycl	56	36	prodrug	prodrug	NN
cord-352096-cc3dzycl	56	37	,	,	,
cord-352096-cc3dzycl	57	1	in	in	IN
cord-352096-cc3dzycl	57	2	HCV	HCV	NNP
cord-352096-cc3dzycl	57	3	-	-	HYPH
cord-352096-cc3dzycl	57	4	infected	infect	VBN
cord-352096-cc3dzycl	57	5	subjects	subject	NNS
cord-352096-cc3dzycl	57	6	with	with	IN
cord-352096-cc3dzycl	57	7	and	and	CC
cord-352096-cc3dzycl	57	8	without	without	IN
cord-352096-cc3dzycl	57	9	cirrhosis	cirrhosis	NN
cord-352096-cc3dzycl	57	10	AT-527	AT-527	NNP
cord-352096-cc3dzycl	57	11	is	be	VBZ
cord-352096-cc3dzycl	57	12	a	a	DT
cord-352096-cc3dzycl	57	13	potent	potent	JJ
cord-352096-cc3dzycl	57	14	in	in	IN
cord-352096-cc3dzycl	57	15	vitro	vitro	FW
cord-352096-cc3dzycl	57	16	replication	replication	NN
cord-352096-cc3dzycl	57	17	inhibitor	inhibitor	NN
cord-352096-cc3dzycl	57	18	of	of	IN
cord-352096-cc3dzycl	57	19	SARS	SARS	NNP
cord-352096-cc3dzycl	57	20	-	-	HYPH
cord-352096-cc3dzycl	57	21	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	57	22	,	,	,
cord-352096-cc3dzycl	57	23	the	the	DT
cord-352096-cc3dzycl	57	24	virus	virus	NN
cord-352096-cc3dzycl	57	25	responsible	responsible	JJ
cord-352096-cc3dzycl	57	26	for	for	IN
cord-352096-cc3dzycl	57	27	the	the	DT
cord-352096-cc3dzycl	57	28	COVID-19	COVID-19	NNP
cord-352096-cc3dzycl	57	29	pandemic	pandemic	NN
cord-352096-cc3dzycl	57	30	Triple	triple	JJ
cord-352096-cc3dzycl	57	31	combination	combination	NN
cord-352096-cc3dzycl	57	32	of	of	IN
cord-352096-cc3dzycl	57	33	interferon	interferon	NN
cord-352096-cc3dzycl	57	34	beta-1b	beta-1b	NNP
cord-352096-cc3dzycl	57	35	,	,	,
cord-352096-cc3dzycl	57	36	lopinavir	lopinavir	NNS
cord-352096-cc3dzycl	57	37	-	-	HYPH
cord-352096-cc3dzycl	57	38	ritonavir	ritonavir	NNS
cord-352096-cc3dzycl	57	39	,	,	,
cord-352096-cc3dzycl	57	40	and	and	CC
cord-352096-cc3dzycl	57	41	ribavirin	ribavirin	NN
cord-352096-cc3dzycl	57	42	in	in	IN
cord-352096-cc3dzycl	57	43	the	the	DT
cord-352096-cc3dzycl	57	44	treatment	treatment	NN
cord-352096-cc3dzycl	57	45	of	of	IN
cord-352096-cc3dzycl	57	46	patients	patient	NNS
cord-352096-cc3dzycl	57	47	admitted	admit	VBN
cord-352096-cc3dzycl	57	48	to	to	IN
cord-352096-cc3dzycl	57	49	hospital	hospital	NN
cord-352096-cc3dzycl	57	50	with	with	IN
cord-352096-cc3dzycl	57	51	COVID-19	COVID-19	NNP
cord-352096-cc3dzycl	57	52	:	:	:
cord-352096-cc3dzycl	57	53	an	an	DT
cord-352096-cc3dzycl	57	54	open	open	JJ
cord-352096-cc3dzycl	57	55	-	-	HYPH
cord-352096-cc3dzycl	57	56	label	label	NN
cord-352096-cc3dzycl	57	57	,	,	,
cord-352096-cc3dzycl	57	58	randomised	randomised	JJ
cord-352096-cc3dzycl	57	59	,	,	,
cord-352096-cc3dzycl	57	60	phase	phase	NN
cord-352096-cc3dzycl	57	61	2	2	CD
cord-352096-cc3dzycl	57	62	trial	trial	NN
cord-352096-cc3dzycl	57	63	SARS	SARS	NNP
cord-352096-cc3dzycl	57	64	-	-	HYPH
cord-352096-cc3dzycl	57	65	CoV-2	CoV-2	NNP
cord-352096-cc3dzycl	57	66	cell	cell	NN
cord-352096-cc3dzycl	57	67	entry	entry	NN
cord-352096-cc3dzycl	57	68	depends	depend	VBZ
cord-352096-cc3dzycl	57	69	on	on	IN
cord-352096-cc3dzycl	57	70	ACE2	ACE2	NNP
cord-352096-cc3dzycl	57	71	and	and	CC
cord-352096-cc3dzycl	57	72	TM	TM	NNP
cord-352096-cc3dzycl	57	73	-	-	HYPH
cord-352096-cc3dzycl	57	74	PRSS2	PRSS2	NNP
cord-352096-cc3dzycl	57	75	and	and	CC
cord-352096-cc3dzycl	57	76	is	be	VBZ
cord-352096-cc3dzycl	57	77	blocked	block	VBN
cord-352096-cc3dzycl	57	78	by	by	IN
cord-352096-cc3dzycl	57	79	a	a	DT
cord-352096-cc3dzycl	57	80	clinically	clinically	RB
cord-352096-cc3dzycl	57	81	proven	prove	VBN
cord-352096-cc3dzycl	57	82	protease	protease	NN
cord-352096-cc3dzycl	57	83	inhibitor	inhibitor	NN
cord-352096-cc3dzycl	58	1	The	the	DT
cord-352096-cc3dzycl	58	2	innate	innate	JJ
cord-352096-cc3dzycl	58	3	immune	immune	JJ
cord-352096-cc3dzycl	58	4	system	system	NN
cord-352096-cc3dzycl	58	5	:	:	:
cord-352096-cc3dzycl	58	6	fighting	fighting	NN
cord-352096-cc3dzycl	58	7	on	on	IN
cord-352096-cc3dzycl	58	8	the	the	DT
cord-352096-cc3dzycl	58	9	front	front	JJ
cord-352096-cc3dzycl	58	10	lines	line	NNS
cord-352096-cc3dzycl	58	11	or	or	CC
cord-352096-cc3dzycl	58	12	fanning	fan	VBG
cord-352096-cc3dzycl	58	13	the	the	DT
cord-352096-cc3dzycl	58	14	flames	flame	NNS
cord-352096-cc3dzycl	58	15	of	of	IN
cord-352096-cc3dzycl	58	16	COVID-19	covid-19	NN
cord-352096-cc3dzycl	58	17	?	?	.
cord-352096-cc3dzycl	59	1	Dexamethasone	Dexamethasone	NNP
cord-352096-cc3dzycl	59	2	in	in	IN
cord-352096-cc3dzycl	59	3	hospitalized	hospitalize	VBN
cord-352096-cc3dzycl	59	4	patients	patient	NNS
cord-352096-cc3dzycl	59	5	with	with	IN
cord-352096-cc3dzycl	59	6	Covid-19	Covid-19	NNP
cord-352096-cc3dzycl	59	7	-preliminary	-preliminary	NNP
cord-352096-cc3dzycl	59	8	report	report	NN
cord-352096-cc3dzycl	59	9	Inhibition	Inhibition	NNP
cord-352096-cc3dzycl	59	10	of	of	IN
cord-352096-cc3dzycl	59	11	the	the	DT
cord-352096-cc3dzycl	59	12	in	in	FW
cord-352096-cc3dzycl	59	13	vitro	vitro	FW
cord-352096-cc3dzycl	59	14	infectivity	infectivity	NN
cord-352096-cc3dzycl	59	15	and	and	CC
cord-352096-cc3dzycl	59	16	cytopathic	cytopathic	JJ
cord-352096-cc3dzycl	59	17	effect	effect	NN
cord-352096-cc3dzycl	59	18	of	of	IN
cord-352096-cc3dzycl	59	19	human	human	JJ
cord-352096-cc3dzycl	59	20	T	T	NNP
cord-352096-cc3dzycl	59	21	-	-	HYPH
cord-352096-cc3dzycl	59	22	lymphotrophic	lymphotrophic	NNP
cord-352096-cc3dzycl	59	23	virus	virus	NN
cord-352096-cc3dzycl	59	24	type	type	NN
cord-352096-cc3dzycl	59	25	III	III	NNP
cord-352096-cc3dzycl	59	26	/	/	SYM
cord-352096-cc3dzycl	59	27	lymphadenopathyassociated	lymphadenopathyassociated	JJ
cord-352096-cc3dzycl	59	28	virus	virus	NN
cord-352096-cc3dzycl	59	29	(	(	-LRB-
cord-352096-cc3dzycl	59	30	HTLV	HTLV	NNP
cord-352096-cc3dzycl	59	31	-	-	HYPH
cord-352096-cc3dzycl	59	32	III	III	NNP
cord-352096-cc3dzycl	59	33	/	/	SYM
cord-352096-cc3dzycl	59	34	LAV	LAV	NNP
cord-352096-cc3dzycl	59	35	)	)	-RRB-
cord-352096-cc3dzycl	59	36	by	by	IN
cord-352096-cc3dzycl	59	37	2',3'-dideoxynucleosides	2',3'-dideoxynucleosides	CD
cord-352096-cc3dzycl	59	38	Novel	Novel	NNP
cord-352096-cc3dzycl	59	39	bis	bis	NNP
cord-352096-cc3dzycl	59	40	-	-	HYPH
cord-352096-cc3dzycl	59	41	tetrahydrofuranylurethanecontaining	tetrahydrofuranylurethanecontaine	VBG
cord-352096-cc3dzycl	59	42	nonpeptidic	nonpeptidic	NN
cord-352096-cc3dzycl	59	43	protease	protease	NN
cord-352096-cc3dzycl	59	44	inhibitor	inhibitor	NN
cord-352096-cc3dzycl	59	45	(	(	-LRB-
cord-352096-cc3dzycl	59	46	PI	PI	NNP
cord-352096-cc3dzycl	59	47	)	)	-RRB-
cord-352096-cc3dzycl	59	48	UIC-94017	UIC-94017	.
cord-352096-cc3dzycl	59	49	(	(	-LRB-
cord-352096-cc3dzycl	59	50	TMC114	TMC114	NNP
cord-352096-cc3dzycl	59	51	)	)	-RRB-
cord-352096-cc3dzycl	59	52	with	with	IN
cord-352096-cc3dzycl	59	53	potent	potent	JJ
cord-352096-cc3dzycl	59	54	activity	activity	NN
cord-352096-cc3dzycl	59	55	against	against	IN
cord-352096-cc3dzycl	59	56	multi	multi	JJ
cord-352096-cc3dzycl	59	57	-	-	JJ
cord-352096-cc3dzycl	59	58	PI	pi	JJ
cord-352096-cc3dzycl	59	59	-	-	HYPH
cord-352096-cc3dzycl	59	60	resistant	resistant	JJ
cord-352096-cc3dzycl	59	61	human	human	JJ
cord-352096-cc3dzycl	59	62	immunodeficiency	immunodeficiency	NN
cord-352096-cc3dzycl	59	63	virus	virus	NN
cord-352096-cc3dzycl	59	64	in	in	IN
cord-352096-cc3dzycl	59	65	vitro	vitro	NNP
cord-352096-cc3dzycl	59	66	2'-Deoxy-4'-C	2'-deoxy-4'-c	CD
cord-352096-cc3dzycl	59	67	-	-	:
cord-352096-cc3dzycl	59	68	ethynyl-2-fluoroadenosine	ethynyl-2-fluoroadenosine	NN
cord-352096-cc3dzycl	59	69	:	:	:
cord-352096-cc3dzycl	60	1	a	a	DT
cord-352096-cc3dzycl	60	2	nucleoside	nucleoside	NN
cord-352096-cc3dzycl	60	3	reverse	reverse	JJ
cord-352096-cc3dzycl	60	4	transcriptase	transcriptase	NN
cord-352096-cc3dzycl	60	5	inhibitor	inhibitor	NN
cord-352096-cc3dzycl	60	6	with	with	IN
cord-352096-cc3dzycl	60	7	highly	highly	RB
cord-352096-cc3dzycl	60	8	potent	potent	JJ
cord-352096-cc3dzycl	60	9	activity	activity	NN
cord-352096-cc3dzycl	60	10	against	against	IN
cord-352096-cc3dzycl	60	11	all	all	DT
cord-352096-cc3dzycl	60	12	HIV-1	HIV-1	NNP
cord-352096-cc3dzycl	60	13	strains	strain	NNS
cord-352096-cc3dzycl	60	14	,	,	,
cord-352096-cc3dzycl	60	15	favorable	favorable	JJ
cord-352096-cc3dzycl	60	16	toxic	toxic	JJ
cord-352096-cc3dzycl	60	17	profiles	profile	NNS
cord-352096-cc3dzycl	60	18	and	and	CC
cord-352096-cc3dzycl	60	19	stability	stability	NN
cord-352096-cc3dzycl	60	20	in	in	IN
cord-352096-cc3dzycl	60	21	plasma	plasma	NN